Liberty Publishing House
New York-2025

LIBERTY
Academic Books

MICROBIOTA INTERACTIONS: NEUROBIOLOGICAL, METALLURGICAL, AND METABOLIC PERSPECTIVES



EDITORS
Dr. Zouaoui SARRA
Dr. Demet CELEBİ

MICROBIOTA INTERACTIONS: NEUROBIOLOGICAL, METALLURGICAL, AND METABOLIC PERSPECTIVES - 2025

ISBN: 979-8-89695-121-6

DOI: https://doi.org/10.5281/zenodo.16488188

Edited By

Dr. Zouaoui SARRA

Dr. Demet CELEBİ

July / 2025

New York / USA



Date: 27.07.2025

Liberty Publishing House
Water Street Corridor New York, NY 10038
www.libertyacademicbooks.com
+1 (314) 597-0372

adopted by Mariam Rasulan&Merve Küçük
ISBN: 979-8-89695-121-6

MICROBIOTA INTERACTIONS: NEUROBIOLOGICAL, METALLURGICAL, AND METABOLIC PERSPECTIVES

EDITORS

Dr. Zouaoui SARRA

Dr. Demet CELEBİ

AUTHORS

Assoc. Prof. Dr. Bashir ABDULKADIR
Dr. Zouaoui SARRA
Dr. Mahmut UÇAR
Manoj Kumar BHATNAGAR
Dharmendra KUMAR
Rouabhi RACHID
Burhan KHALID
Musrat SHAHEEN
Humaira MUZAFFAR
Sidra ALTAF
Ghulam HUSSAIN
Arslan IFTIKHAR
Imran MUKHTAR
Misbah BATOOL
Maham FATIMA
Asma HUSSAIN
Haseeb ANWAR
Aminu Ibrahim BELLO
Yahaya Riko YUNUSA
Salihu SALISU
S. KALAISELVAN
M. Devi SRI
K. Mohana PRIYA
V. JEEVANANTHAN
Hatun Şevval SAĞIN

TABLE OF CONTENTS

PREFACE

The pursuit of scientific inquiry has long endeavored to unravel the intricate and often imperceptible systems that underpin both natural and anthropogenic phenomena, with the ultimate objective of advancing human understanding and improving societal welfare. This volume, Microbiota Interactions: Neurobiological, Metallurgical, and Metabolic Perspectives, epitomizes such an endeavor by presenting an inherently interdisciplinary synthesis of scholarship concerning the multifaceted roles of microbiota within human health, environmental sustainability, and industrial preservation practices. In so doing, it highlights the microbiota not merely as a biological entity of intrinsic interest but as a pivotal determinant in shaping ecological equilibria, biochemical resilience, and therapeutic innovation.

The chapters compiled herein traverse a remarkably diverse thematic spectrum. Topics range from the microbial determinants of corrosion and conservation in archaeological copper artifacts, through the perturbations of gut microbial communities induced by neonicotinoid exposure, to the intricate pathophysiological implications of microbiome dysbiosis in metabolic and neurodegenerative disorders, and ultimately to emergent therapeutic strategies leveraging microbiota modulation. Collectively, these contributions coalesce into a comprehensive, multi-perspective body of knowledge that not only chronicles the state of the field but also illuminates its prospective trajectories. This work has been rendered possible through the intellectual diligence and scholarly commitment of its contributors, whose expertise has imbued the volume with a distinctive scientific rigor and conceptual depth. To all authors who have contributed their insights, analyses, and critical perspectives, we extend our profound gratitude.

It is our conviction that this volume will serve as both a reference point and a source of intellectual stimulation for academics, researchers, and professionals seeking to engage with the complex intersections of microbiota, human health, and environmental interactions. In the spirit of scientific knowledge as a shared and cumulative enterprise, we hope that the insights contained herein will foster novel investigations, inform evidence-based practices, and inspire new paradigms of interdisciplinary collaboration.

Editors
Dr. Zouaoui SARRA
Dr. Demet CELEBİ

CHAPTER 1
THE IMPACT OF ARCHAEOLOGICAL COPPER ARTIFACTS ON MICROBIOTA AND STRATEGIES FOR THEIR CONSERVATION

Manoj Kumar BHATNAGAR[1]
Dharmendra KUMAR[2]

[1] Science Branch, Pt. Deen Dayal Upadhyay Institute of Archaeology, Archaeological Survey of India, Greater Noida-201310, paldkasi@gmail.com
[2] Science Branch, Pt. Deen Dayal Upadhyay Institute of Archaeology, Archaeological Survey of India, Greater Noida

INTRODUCTION

Copper has been integral to the advancement of human civilization for millennia, playing a vital role in the development of tools, weapons, currency, and art. Its use dates back to the earliest stages of human history, from the creation of bronze alloys to the crafting of intricate artifacts in ancient cultures. The enduring presence of copper artifacts in archaeological sites offers a valuable window into past societies, providing essential insights into technological advancements, cultural practices, and economic systems. These artifacts serve not only as physical representations of ancient life but also as crucial elements for historical and scientific research [1]. However, as with all materials, copper is subject to the effects of time, environmental conditions, and, notably, microbial activity, all of which can significantly impact the preservation of these objects.

Over time, copper artifacts, whether buried in archaeological sites or displayed in museums, are vulnerable to a variety of natural degradation processes. While environmental factors such as moisture, temperature, and air pollution contribute to the corrosion of copper, one of the most significant and often overlooked contributors to copper degradation is the activity of microorganisms. Bacteria, fungi, algae, and other microbial agents can colonize copper surfaces, initiating biochemical processes that lead to corrosion, surface alteration, and the breakdown of the material. These microorganisms thrive in environments where copper artifacts are exposed to moisture, oxygen, and other organic substances. Microbial colonies form biofilms on the surface of the copper, creating a localized microenvironment that accelerates the degradation of the metal [2-3] .

The interaction between microbiota and copper artifacts is complex, as different microbial species can have varying impacts on the corrosion process. For instance, some bacteria, such as sulfate-reducing bacteria (SRB), can produce hydrogen sulfide (H_2S), which reacts with copper to form copper sulfide, a compound that leads to corrosion. Other microorganisms, like certain fungi and algae, may excrete organic acids or other byproducts that can further accelerate the breakdown of the metal [4]. The metabolic activities of these microorganisms often lead to localized corrosion, pitting, and surface staining, all of which compromise the structural integrity of the artefact [5].

One of the most concerning aspects of microbial-induced corrosion is its ability to undermine the long-term preservation of archaeological copper artifacts. Over time, microbial activity can cause irreversible damage to the surface layers of copper, resulting in the loss of original features and details that are vital to the historical value of the object. The process of corrosion can also lead to the formation of patinas or crusts that obscure the artifact's original appearance, making it difficult for researchers and historians to accurately analyze its age, composition, and function. As microbial corrosion progresses, it can also weaken the artifact, making it more susceptible to physical damage during handling, transportation, or exhibition [6,7].

Given the significant role that microorganisms play in the degradation of copper artifacts, it is crucial to understand the mechanisms underlying microbial corrosion and the factors that contribute to its progression [8]. This knowledge is essential for developing effective conservation strategies that can mitigate the impact of microbiota on copper artifacts. In recent years, significant advancements have been made in the field of conservation science, particularly in the development of methods to prevent or slow the corrosion of copper and other metals. These strategies range from environmental control measures, such as adjusting humidity and temperature levels, to the application of protective coatings and chemical treatments that inhibit microbial growth.

Conservation practices must also take into account the balance between preserving the artifact's physical integrity and ensuring its historical authenticity. In many cases, conservation efforts focus not only on halting the corrosion process but also on restoring the artifact to a condition that reflects its original appearance, without compromising its historical significance. This delicate balance requires a deep understanding of both the material properties of copper and the biological factors that contribute to its deterioration [9].

One of the key challenges in developing effective conservation strategies is the diversity of microbial communities that can affect copper artifacts. Different environmental conditions, such as the presence of organic material, moisture, and temperature, can promote the growth of distinct microbial species, each with its own corrosion potential. As a result, conservation strategies must be tailored to the specific conditions in which the artifact is found or displayed. For example, copper artifacts recovered from underwater

sites may require different treatments compared to those found in dry, controlled museum environments [10].

This chapter aims to provide a comprehensive overview of the interaction between microbial communities and archaeological copper artifacts, focusing on the mechanisms of corrosion and the impact of microbial activity on the preservation of these objects. It will also explore current conservation strategies and the latest advancements in the field, highlighting the importance of a multidisciplinary approach that combines scientific research, materials science, and conservation practices. Ultimately, the goal is to offer effective solutions that ensure the long-term preservation of copper artifacts, allowing future generations to continue to appreciate and learn from these invaluable links to our shared past.

1. MICROBIOTA AND COPPER ARTIFACT DEGRADATION

1.1 Microbial Corrosion of Copper

Microbial corrosion, often referred to as biocorrosion or biodeterioration, is a biological process in which microorganisms contribute to the decay of materials, including metals like copper. In the context of archaeological copper artifacts, microbial corrosion can manifest in several forms

1.1.1 Sulfate-Reducing Bacteria (SRB)

These bacteria, particularly Desulfovibrio and Desulfobacterium species, are well-known for their role in metal corrosion. SRB reduce sulfate ions (SO_4^{2-}) to hydrogen sulfide (H_2S), which reacts with copper to form copper sulfide (CuS), leading to corrosion. This process accelerates in anaerobic environments, such as those found in buried artifacts [4, 7, 11].

Mechanism:

Sulfate-reducing bacteria (SRB) utilize sulfate (SO_4^{2-}) as a terminal electron acceptor in their metabolism under anaerobic conditions. This reduction process produces hydrogen sulfide (H_2S) as a byproduct. The overall chemical reaction for sulfate reduction is:

$$SO_4^{2-} + 8e^- + 4H \rightarrow H_2S + 4H_2O$$

In this process, SO_4^{2-} (sulfate) is reduced to H_2S (hydrogen sulfide) and the electrons (e^-) required for this reduction are obtained from the metabolism of organic compounds by the SRB.

Once hydrogen sulfide is produced, it can react with metals, particularly copper, leading to corrosion. The reaction between hydrogen sulfide (H_2S) and copper (Cu) results in the formation of copper sulfide (CuS), which is a primary product of the corrosion process. The reaction can be described as:

$$Cu + H_2S \rightarrow CuS + H_2$$

In this reaction, Copper (Cu) reacts with hydrogen sulfide (H_2S) to form copper sulfide (CuS) and hydrogen gas (H_2).

The copper sulfide (CuS) that forms is not protective, and it can continue to promote further corrosion by allowing additional H_2S to interact with the metal. Over time, the formation of CuS results in the degradation of the metal surface, leading to corrosion. Additionally, the process can accelerate in anaerobic environments, such as those found in submerged or buried objects, where oxygen is absent, favoring the activity of sulfate-reducing bacteria.

1.1.2 Iron-Reducing Bacteria (IRB)

These microorganisms, including Geobacter species, can also contribute to copper corrosion. They reduce ferric iron (Fe^{3+}) to ferrous iron (Fe^{2+}), which can further interact with copper surfaces, catalyzing oxidative reactions that lead to material degradation [5, 12].

Mechanism:

A. Reduction of Ferric Iron (Fe^{3+}) to Ferrous Iron (Fe^{2+})

Iron-reducing bacteria (IRB) utilize ferric iron (Fe^{3+}) as an electron acceptor under anaerobic conditions. They reduce Fe^{3+} to Fe^{2+} during their metabolic process:

$$Fe^{3+} + e^- \rightarrow Fe^{2+}$$

This reaction generates ferrous iron (Fe^{2+}) from ferric iron (Fe^{3+}), which can then influence the surrounding environment.

B. Interaction of Ferrous Iron (Fe^{2+}) with Copper

The produced ferrous iron (Fe^{2+}) can interact with copper (Cu) in the environment. This reaction can lead to the oxidation of copper and the formation of corrosion products. A potential reaction is:

$Cu + Fe^{2+} \rightarrow Cu^{2+} + Fe^{2+}$ (surface reaction)

In this process, Ferrous iron (Fe^{2+}) can oxidize copper (Cu) to form Cu^{2+} ions on the metal surface. The Cu^{2+} ions can then react with other components, further promoting the degradation of copper.

C. Catalysis of Oxidative Reactions

Ferrous iron (Fe^{2+}) can also catalyze oxidative reactions at the metal surface, further accelerating copper corrosion. This can involve the production of reactive oxygen species (ROS) or interaction with other metals, leading to an overall increase in material degradation.

1.1.3 Fungi and Algae

Fungal species, such as Aspergillus and Penicillium, and various algae species can colonize copper artifacts. They secrete organic acids (like citric acid and oxalic acid), which lower the pH of the surrounding environment, further promoting copper corrosion. Additionally, fungal biofilms can physically abrade the surface of copper, contributing to mechanical wear [13-14].

Mechanism:

A. Secretion of Organic Acids

Fungi and algae secrete organic acids, such as citric acid and oxalic acid, which lower the pH of the surrounding environment. The lower pH increases the solubility of copper, leading to the formation of copper ions (Cu^{2+}):

$Cu + 2H+ \rightarrow Cu^{2+} + H_2$

This acidic environment promotes the dissolution of copper, accelerating corrosion.

B. Physical Abrasion by Fungal Biofilms

Fungal biofilms can physically adhere to copper surfaces and cause mechanical wear. The biofilm structure can contribute to the abrasion of the copper surface, making it more vulnerable to chemical corrosion and further physical degradation over time.

1.1.4 Microbial Biofilms

Microorganisms in the environment form biofilms, which are clusters of microbial cells embedded in a self-produced matrix of extracellular polymeric

substances (EPS) [15]. These biofilms not only protect microorganisms from external stresses but also concentrate corrosive metabolites, which can exacerbate the degradation of copper surfaces.

1.2 Environmental Factors Influencing Microbial Activity

The microbial activity responsible for the corrosion of copper artifacts is highly dependent on environmental factors such as temperature, humidity, and pH [7]. For example:

Temperature

Higher temperatures tend to accelerate microbial metabolism, thereby increasing the rate of corrosion. In contrast, cooler temperatures slow down microbial processes but do not eliminate them completely [16].

Humidity

Copper artifacts in humid environments are particularly susceptible to corrosion, as water facilitates the growth of microorganisms and the transport of ions necessary for corrosion processes [17].

PH Levels

Acidic conditions favor the activity of certain microorganisms, such as sulfur-oxidizing bacteria, which thrive in low pH environments. These microorganisms can significantly enhance the degradation of copper artifacts.

2. MICROBIAL IMPACT ON THE PRESERVATION OF COPPER ARTIFACTS

2.1 Direct Corrosive Effects

Microbial corrosion can directly degrade copper artifacts in several ways:

Pitting Corrosion

Microbial activity can cause localized corrosion known as pitting, where small holes form on the surface of the artifact. This type of corrosion is

particularly damaging because it can significantly compromise the structural integrity of the object without being immediately visible [18].

Patina Formation

While patina (the greenish layer of copper carbonate) is a natural result of copper oxidation and often viewed as a protective coating, excessive microbial interaction can lead to the formation of undesired compounds like copper sulfides or chlorides, which are more detrimental to the artefact [3,6,7].

Surface Biofilm Accumulation

Biofilms can accumulate on the surface of copper artifacts, creating a layer of a microorganism that accelerates the corrosion process by trapping moisture and corrosive agents near the metal surface [5, 13-15].

Indirect Effects on Artifacts' Historical Integrity

The corrosion and degradation caused by microorganisms can also lead to the loss of important historical information. As the metal deteriorates, it can result in the erasure of inscriptions, motifs, and craftsmanship, which are vital for understanding the cultural and historical significance of the artifact.

3. CONSERVATION STRATEGIES FOR COPPER ARTIFACTS AFFECTED BY MICROBIORTA

Effective conservation of archaeological copper artifacts requires a multi-disciplinary approach that combines scientific understanding with practical preservation methods. The following strategies have been developed to protect these artifacts from microbial degradation [3, 6, 10, 14, 18]:

3.1 Preventive Conservation

Environmental Control

Maintaining stable environmental conditions is one of the most effective methods of preventing microbial corrosion. This includes controlling temperature, humidity, and light exposure. Museums and conservation centers typically employ climate-controlled storage environments to limit the growth of microorganisms [9, 14, 17].

Use of Inert Atmospheres

In some cases, copper artifacts are stored in inert atmospheres such as nitrogen or argon gas, which reduce the availability of oxygen and moisture necessary for microbial activity.

3.2 Chemical Treatments

Decontamination with Biocides

Copper artifacts can be treated with biocides to kill harmful microorganisms that may be present. Care must be taken to ensure that the biocides used do not cause further chemical damage to the artifact itself.

Chelating Agents

Chelating agents, such as ethylenediaminetetraacetic acid (EDTA), can be used to remove harmful corrosion products from the surface of the artifact. These agents bind to metal ions like copper, making them more soluble and easier to remove.

Corrosion Inhibition Strategies

To mitigate microbial-induced corrosion and prolong the lifespan of archaeological copper artifacts, corrosion inhibition strategies should be developed.

Benzotriazole (BTA) as a Corrosion Inhibitor is widely recognized as an effective corrosion inhibitor for copper and its alloys. It functions by forming a protective passive layer on the metal surface, preventing further oxidation and microbial-induced degradation [19].

$$Cu + BTA \rightarrow Cu(I)\text{−}BTA$$

This protective layer effectively prevents the interaction of copper with moisture, sulfides, and microbial byproducts like hydrogen sulfide (H_2S), thereby mitigating sulfate-reducing bacteria (SRB)-induced corrosion.

Protective Coatings

Copper artifacts can be coated with protective films, such as PVA or other polymer-based materials, to create a barrier between the metal and the

environment. These coatings prevent direct microbial interaction with the copper surface.

3.3 Biological and Enzymatic Treatments

Recent advancements in biocorrosion management have led to the development of enzymatic treatments. Enzymes that break down the extracellular polymers in biofilms have shown promise in reducing the microbial impact on copper surfaces. Additionally, research into the use of non-toxic, naturally occurring microorganisms that inhibit pathogenic microbial growth is also being explored.

3.4 Physical Cleaning and Stabilization

Laser Cleaning

Laser technology is increasingly being used for the conservation of copper artifacts. Lasers can precisely target and remove corrosion without damaging the underlying metal, offering a non-invasive alternative to traditional cleaning methods.

Electrochemical Stabilization

In certain cases, electrochemical methods have been employed to stabilize corroded copper artifacts. This technique uses electrical currents to reverse some of the corrosion processes, thus helping to restore the artifact's original properties.

CONCLUSION

The interaction between archaeological copper artifacts and microbiota is a complex phenomenon that influences both artifact preservation and deterioration. While copper's antimicrobial properties limit microbial colonization, specific microbial communities can accelerate corrosion through biofilm formation and enzymatic oxidation. Conservation strategies must be tailored to mitigate microbial-induced degradation while preserving beneficial microbial interactions. Integrating microbiology, chemistry, and materials science will be essential for developing innovative conservation techniques that ensure the long-term stability of copper-based cultural heritage.

REFERANCES

Alessia Artesani, Francesca Di Turo, Margherita Zucchelli , Arianna Traviglia, Recent Advances in Protective Coatings for Cultural Heritage–An Overview, Coatings 2020, 10, 217; doi:10.3390/coatings10030217.

Anders G. Nord, Kate Tronner, Einar Mattsson, Gunnar Ch. Borg and Inga Ullen, Environmental Threats to Buried Archaeological Remains, Ambio Vol. 34, No. 3, May 2005.

Bird, L. J., Coleman, M. L., & Newman, D. K. (2013). Iron and Copper Act Synergistically To Delay Anaerobic Growth of Bacteria. Applied and Environmental Microbiology, 79(12), 3619–3627. doi:10.1128/aem.03944-12

Dennis Enning, Julia Garrelfs, Corrosion of Iron by Sulfate-Reducing Bacteria: New Views of an Old Problem, Applied and Environmental Microbiology p. 1226 –1236 February 2014 Volume 80 Number 4.

Donny L. Hamilton, Methods for Conserving Archaeological Material from Underwater Sites, Revision Number 1 January 1, 1999 Anthropology 605 Conservation of Archaeological Resources I Nautical Archaeology Program Department of Anthropology Texas A&M University College Station, Texas 77807

Emine Kutlu , Muhammed Asim Ali, A Review on Conservational Methodologies of Tangible Cultural Artifacts from Environmental Corrosion, International Journal of Environment and Geoinformatics (IJEGEO), 11(3): 024-029. doi. 10.30897/ijegeo.1478498

Gadd, G. M. (2012). Microbial Roles in Mineral Transformations and Metal Cycling in the Earth's Critical Zone. Molecular Environmental Soil Science, 115–165. doi:10.1007/978-94-007-4177-5_6

Geoffrey Michael Gadd , Marina Fomina , Flavia Pinzari, Fungal biodeterioration and preservation of cultural heritage, artwork, and historical artifacts: extremophily and adaptation, Microbiol Mol Biol Rev. 2024 Jan 5;88(1):e00200-22. doi: 10.1128/mmbr.00200-22

Herrling, M. P., Lackner, S., Nirschl, H., Horn, H., & Guthausen, G. (2019). Recent NMR/MRI studies of biofilm structures and dynamics. Annual Reports on NMR Spectroscopy. doi:10.1016/bs.arnmr.2019.02.001

K. M. Daraina, M. Z. Jumaat, S. M. Nazimuddina, A. Ahsanc, R. Rashid, M. M. A. Aziz, M. Obaydullah, A. B. M. S. Islam, A Review of the Corrosion Behavior of Metallic Heritage Structures and Artifacts, Jurnal Teknologi (Sciences & Engineering) 77:1 (2015) 205–218

Khadija Elmouaden, Shehdeh Jodeh, Aicha Chaouay, Rachid Oukhrib, Rachid Salghi, Lahcen Bazzi, Mustapha Hilali, Sulfate-Reducing Bacteria Impact on Copper Corrosion Behavior in Natural Seawater Environment, Journal of Surface Engineered Materials and Advanced Technology, 6, 36-46. http://dx.doi.org/10.4236/jsemat.2016.62004

M.A. Javed, W.C. Neil , G. McAdam, S.A. Wade, Microbiologically Influenced Corrosion of Copper and Its Alloys-A Review, Corrosion & Prevention 2016 Paper 84.

Manoj Kumar Bhatnagar , Sanjay Kumar Manjul , Rina Parmar , Dharmendra Kumar, Restoration, preservation, and interpretation of the royal chariot from the Sinauli excavation in India: Safeguarding a remarkable discovery, Arts & Communication. 2024;2(4):2437. doi: 10.36922/ac.2437

Mark Pearce, The 'Copper Age'—A History of the Concept, Journal of World Prehistory (2019) 32:229–250. https://doi.org/10.1007/s10963-019-09134-z.

Mohamed Abdelbar, Ashraf M. El Shamy, Understanding soil factors in corrosion and conservation of buried bronze statuettes: insights for preservation strategies, Scientifc Reports | (2024) 14:19230 | https://doi.org/10.1038/s41598-024-69490-5

O. P. Agrawal, Conservation of Metals in Humid Climate Proceedings of the Asian Regional Seminar held from 7---12 December, 1987, https://www.iccrom.org/sites/default/files/2018-02/1989_agrawal_metals_humid_lucknow_47324_light.pdf

Sachie Welikala, Saad Al-Saadi, Will P. Gates, Christopher Panter, R. K. Singh Raman,), Sulphate reducing bacteria (SRB) biofilm development and its role in microbial corrosion of carbon steel. Front. Mater. 2024, 11:1360869. doi: 10.3389/fmats.2024.1360869

Victoria, S. N., Sharma, A., & Manivannan, R. (2021). Metal corrosion induced by microbial activity – Mechanism and control options. Journal of the Indian Chemical Society, 98(6), 100083. doi:10.1016/j.jics.2021.100083

Zhao, J., Csetenyi, L., & Gadd, G. M. (2020). Biocorrosion of copper metal by Aspergillus niger. International Biodeterioration & Biodegradation, 154, 105081. doi:10.1016/j.ibiod.2020.105081

CHAPTER 2
GUT MICROBIOTA AND NEONICOTINOID TOXICITY: MOLECULAR PATHWAYS AND NEUROPROTECTIVE STRATEGIES

[1]Dr. Zouaoui SARRA
[2]Rouabhi RACHID
[3]Dr. Mahmut UÇAR

[1]Larbi Tebessi University, Applied Biology Department, Tebessa, Algeria, sarra.zouaoui@univ-tebessa.dz
[2]Larbi Tebessi University, Toxicology And Ecosystem Pathologies Laboratory, SESNV Faculty
[3] Yakutiye Municipality, 0000-0003-2740-6476

INTRODUCTION

In recent years, there has been a growing body of evidence highlighting the pivotal role of gut microbiota in maintaining overall health, particularly in the regulation of brain function through the gut-brain axis (GBA). The GBA represents a highly intricate bidirectional communication network linking the gut and the central nervous system (CNS), primarily mediated through neural, immune, endocrine, and metabolic pathways. This interplay underscores the gut microbiota's profound influence on various neurophysiological processes, including neurotransmitter synthesis, neuroinflammation regulation, immune modulation, and short-chain fatty acid (SCFA) production. These mechanisms collectively shape brain homeostasis and are essential for cognitive function, emotional regulation, and neuroprotection against environmental toxins and neurodegenerative diseases (Cryan et *al.,* 2019; Carabotti et *al*., 2015).

Among environmental neurotoxicants, neonicotinoid pesticides have emerged as a significant public health concern due to their widespread use in modern agriculture. These insecticides, particularly Imidacloprid (IMI), are known for their potent action on insect nicotinic acetylcholine receptors (nAChRs). However, accumulating research has demonstrated that these chemicals also exert neurotoxic effects in mammals, including humans, due to their ability to cross the blood-brain barrier and interfere with neuronal signaling (Tomizawa & Casida, 2005). The chronic exposure to IMI has been linked to oxidative stress, mitochondrial dysfunction, neuroinflammation, and alterations in neurotransmitter balance, all of which contribute to cognitive impairments and neurodegenerative processes (Gibbons et *al*., 2015).

Beyond direct neurotoxicity, recent studies suggest that neonicotinoids may also disrupt the gut microbiome, altering the composition and diversity of intestinal microbial communities (Lerner et *al*., 2017; Zhang et *al*., 2020). Given the strong connection between gut microbiota and brain function, this disruption can have far-reaching implications for neurological health. Research indicates that IMI-induced dysbiosis is associated with increased gut permeability, systemic inflammation, and dysregulated microbial metabolism, all of which contribute to neurodegenerative processes (Joly et *al.*, 2021).

Changes in gut microbial populations may further impact the production of key neuroactive compounds such as gamma-aminobutyric acid (GABA), serotonin, dopamine, and SCFAs, which are essential for proper CNS function and neuroprotection (Sharon et *al.*, 2016).

A crucial aspect of mitigating the neurotoxic effects of neonicotinoids involves antioxidant and anti-inflammatory interventions, particularly the use of medicinal plant extracts rich in bioactive compounds. Among these, Melissa *officinalis* L. (lemon balm) has gained significant attention due to its high content of polyphenols, flavonoids, and rosmarinic acid, which exhibit potent antioxidant and neuroprotective properties. Several studies have demonstrated that Melissa *officinalis* L. can reduce oxidative stress by enhancing endogenous antioxidant defenses, such as glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT), while simultaneously decreasing lipid peroxidation markers such as malondialdehyde (MDA) (Kara et *al*., 1983; Kennedy et *al*., 2003). These effects are particularly relevant in counteracting IMI-induced mitochondrial dysfunction and neuronal damage.

Furthermore, Melissa *officinalis* L. has been shown to exert beneficial effects on gut microbiota composition, potentially restoring microbial balance and mitigating pesticide-induced dysbiosis (Omar et *al*., 2022). By promoting the growth of beneficial gut bacteria such as Lactobacillus and Bifidobacterium while inhibiting pathogenic strains, lemon balm extract may help maintain gut integrity and reduce inflammation-mediated neurotoxicity. This suggests that the gut microbiota could serve as a novel therapeutic target in pesticide-induced neurotoxicity, and the use of plant-based interventions could provide a promising strategy for neuroprotection.

Given the increasing prevalence of pesticide exposure and its potential impact on human health, it is imperative to further explore the molecular mechanisms underlying gut microbiota-mediated neurotoxicity and identify effective protective strategies. This review aims to provide a comprehensive analysis of the interplay between neonicotinoid pesticides, gut microbiota, and neurotoxicity, while highlighting the potential of antioxidant phytochemicals, particularly Melissa *officinalis* L., in mitigating these detrimental effects. Understanding these mechanisms could pave the way for novel therapeutic

approaches that leverage microbiome modulation to combat pesticide-induced neurological disorders.

Objectives of the Study

1. Investigate the effect of IMI on gut microbiota composition and function.
2. Examine the relationship between microbial changes and neonicotinoid-induced neurotoxicity.
3. Analyze the molecular mechanisms linking microbiota dysbiosis and neuroinflammation.
4. Compare IMI with other neonicotinoid pesticides to assess the specificity of its effects.
5. Explore therapeutic potential using Melissa *officinalis* and probiotics as protective agents.

1. EFFECTS OF IMIDACLOPRID ON THE GUT-BRAIN AXIS

Emerging research highlights the significant impact of pesticide exposure on gut microbiota composition and its subsequent effects on neurological health. Chronic exposure to imidacloprid (IMI), a widely used neonicotinoid insecticide, has been associated with profound disruptions in gut microbial communities, leading to adverse consequences on the gut-brain axis (GBA). The gut microbiota, which plays a crucial role in maintaining homeostasis through immune regulation, neurotransmitter synthesis, and short-chain fatty acid (SCFA) production, becomes imbalanced under pesticide stress, potentially exacerbating neuroinflammatory and neurodegenerative processes.

Studies have demonstrated that prolonged exposure to IMI results in a significant reduction in microbial diversity, a key indicator of gut health. Specifically, IMI exposure has been found to selectively increase the prevalence of pathogenic, inflammation-associated bacterial strains such as *Escherichia coli*, while simultaneously decreasing beneficial commensal bacteria involved in SCFA biosynthesis (Li et *al.*, 2020). SCFAs, including butyrate, acetate, and propionate, are essential for maintaining intestinal barrier integrity and modulating neuroinflammatory responses. A reduction in these key metabolites weakens the protective mechanisms that help shield the brain from oxidative stress and inflammation, thereby increasing vulnerability to neurotoxic damage.

Furthermore, the imbalance in gut microbiota composition induced by IMI has been linked to heightened systemic inflammation and oxidative stress, two key contributors to neurotoxicity. Dysbiosis can trigger intestinal permeability (leaky gut syndrome), allowing bacterial endotoxins such as lipopolysaccharides (LPS) to enter the bloodstream. This results in the activation of immune pathways and the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, which can cross the blood-brain barrier and contribute to neuroinflammation. Consequently, the disrupted gut ecosystem fails to regulate neurotransmitter homeostasis, particularly affecting the synthesis and availability of serotonin, dopamine, and gamma-aminobutyric acid (GABA)—neurochemicals essential for cognitive function, mood regulation, and motor coordination.

In addition to its microbiota-altering effects, IMI has been implicated in the generation of reactive oxygen species (ROS) within the gut, further exacerbating oxidative stress at both the intestinal and neuronal levels. The depletion of antioxidant defense mechanisms, such as glutathione (GSH) and superoxide dismutase (SOD), intensifies lipid peroxidation, mitochondrial dysfunction, and apoptotic signaling in neuronal cells. These processes collectively contribute to cognitive deficits, learning impairments, and behavioral disturbances, which have been observed in experimental models of chronic IMI exposure.

Overall, the interplay between imidacloprid-induced gut dysbiosis, increased inflammation, oxidative stress, and neurotransmitter imbalances underscores the pivotal role of the gut-brain axis in pesticide-mediated neurotoxicity. Understanding these mechanisms provides valuable insights into potential therapeutic interventions, such as the use of probiotics, prebiotics, and antioxidant-rich plant extracts (e.g., Melissa *officinalis* L.), to mitigate the adverse effects of neonicotinoid exposure on brain health.

2. MICROBIOTA COMPOSITION CHANGES FOLLOWING IMI EXPOSURE

Chronic exposure to IMI significantly alters gut microbiota composition by :

- **Decreasing** beneficial bacteria such as *Lactobacillus* and *Bifidobacterium*.
- **Increasing** pathogenic bacteria such as *Proteobacteria* and *Firmicutes*.
- **Reducing** microbiome diversity, weakening the intestinal barrier, and increasing susceptibility to neuroinflammation.

The table shows that IMI exposure significantly reduces beneficial bacteria and increases pathogenic bacteria, contributing to neurological dysfunction.

Table 1: Comparison of beneficial and pathogenic bacteria before and after IMI exposure

Group	***Lactobacillus* (%)**	***Bifidobacterium* (%)**	***Proteobacteria* (%)**	***Firmicutes* (%)**
Pre-exposure	45.2 ± 2.3	30.1 ± 1.8	12.5 ± 1.2	10.2 ± 0.9
Post-IMI exposure	22.3 ± 2.0	15.4 ± 1.5	35.7 ± 1.8	26.6 ± 2.1

3. IMI'S IMPACT ON SHORT-CHAIN FATTY ACID (SCFA) METABOLISM

Short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate play a crucial role in brain health by reducing inflammation, maintaining the integrity of the blood-brain barrier (BBB), regulating immune cell activity in the brain and promoting neurotransmitter synthesis. These SCFAs are produced through the fermentation of dietary fibers by beneficial gut microbiota, acting as neuroprotective agents against oxidative stress and enhancing neuronal plasticity.

Chronic IMI exposure has been shown to drastically reduce SCFA levels, leading to dysregulated neuroinflammation and an increased risk of neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally,

these changes impair the function of microglia, the brain's immune cells, which play a critical role in maintaining neuroimmune balance. Dysfunctional microglia contribute to oxidative stress accumulation and heightened neuronal apoptosis (Li et *al.*, 2018).

Table 2: SCFA levels in different groups

Group	Butyrate (µmol/g)	Acetate (µmol/g)	Propionate (µmol/g)
Control	35.6 ± 3.2	47.3 ± 2.7	28.9 ± 1.9
IMI Group	18.2 ± 2.1	22.8 ± 1.9	12.5 ± 1.2

These findings indicate that IMI significantly decreases SCFA levels, leading to increased neuroinflammation and cognitive dysfunction.

4. OXIDATIVE STRESS AS A KEY MECHANISM IN IMIDACLOPRID NEUROTOXICITY

Our recent study on the neurological effects of Imidacloprid (IMI) revealed that chronic exposure at doses of 5 and 50 mg/kg/day leads to:

- A decrease in antioxidant levels such as SOD, GPx, and GSH in the brain, reflecting increased oxidative stress.
- Elevated MDA levels, a key marker of lipid peroxidation, indicating cellular membrane damage in the brain **(Zouaoui et *al.,* 2024).**
- Increased caspase-3 and cytochrome-c levels, suggesting the activation of neuroapoptotic pathways.

5. EFFECTS OF IMIDACLOPRID ON THE GUT-BRAIN AXIS AND NEUROMICROBIOTA

5.1. IMI's Impact on Microbiota Composition and Balance

Research indicates that chronic exposure to IMI leads to significant disruptions in gut microbiota composition, negatively affecting nervous system health by reducing beneficial bacteria and increasing inflammation-associated species. For instance, a recent study showed that prolonged IMI exposure caused a significant reduction in Lactobacillus and Bifidobacterium, two

essential bacterial genera involved in neurotransmitter production and cognitive function enhancement (Yang et *al.,* 2021).

Conversely, an increase in Proteobacteria and Firmicutes, bacterial groups linked to neuroinflammatory responses and oxidative stress, was observed. These bacteria activate inflammatory pathways such as TLR4/NF-κB, leading to an immune response surge and increased production of inflammatory cytokines such as TNF-α and IL-6, which contribute to neuroinflammation and neuronal damage.

Furthermore, studies indicate that IMI reduces gut microbiota diversity, weakening the body's resistance to environmental stressors and increasing susceptibility to neurological disorders such as depression, anxiety, and Parkinson's disease (Chen et *al.,* 2020). This suggests that IMI-induced microbiota alterations extend beyond digestive health, directly impacting the central nervous system and reinforcing the strong connection between gut and brain health.

6. NEUROTOXIC EFFECTS OF IMIDACLOPRID

6.1 Molecular Effects on Nicotinic Acetylcholine Receptors (nAChRs)

IMI acts as a neurotoxicant by interacting with nAChRs, which play essential roles in neurotransmission, learning, and memory (Tomizawa and Casida, 2005). IMI binding results in excessive receptor stimulation, oxidative stress, and an increase in intracellular calcium levels, promoting neuroinflammation and apoptosis (Li et *al*., 2018).

6.2 Effects on Oxidative Stress and Neuroinflammation

Chronic IMI exposure leads to:

- **Reduction in antioxidant levels** such as GSH and antioxidant enzymes (CAT, SOD) **(Bal et *al.*, 2012).**
- **Increase in lipid peroxidation (MDA)**, indicating neural tissue damage **(Duzguner & Erdogan, 2010).**
- **Elevated pro-inflammatory cytokines** such as TNF-α and IL-6, linked to neurodegenerative diseases like Alzheimer's and Parkinson's **(Abd-Elhakim et *al.*, 2021)**

6.3 Effects of IMI on Gene Expression in the Gut-Brain Axis

Genomic studies have shown that IMI can influence the gene expression of proteins involved in neuroinflammation and short-chain fatty acid (SCFA) metabolism. In a recent study, gene expression levels were analyzed after IMI exposure using RT-qPCR, with the following results:

Gene	Function	Expression in Control Group (100%)	Expression After IMI Exposure (%)
TNF-α	Major inflammatory factor	100%	175% ↑
IL-6	Neuroinflammatory promoter	100%	160% ↑
NF-κB	Regulates inflammatory response	100%	190% ↑
BDNF	Neurotrophic growth factor	100%	60% ↓
SCFA receptor (GPR41)	Regulates neuro-metabolism	100%	50% ↓

Key Findings:

- Gene expression levels of **TNF-α, IL-6, and NF-κB** significantly increased, indicating neuroinflammation activation.
- **BDNF expression decreased**, suggesting potential impairments in cognitive function and learning.
- **GPR41 expression declined**, which may lead to disruptions in SCFA metabolism, crucial for brain health.

7. COMPARING IMI'S EFFECTS WITH OTHER NEONICOTINOID PESTICIDES

Studies suggest that IMI's effects differ from other neonicotinoids, such as Thiamethoxam and Acetamiprid:

- IMI exhibits a higher affinity for nAChRs, increasing its neurotoxic potential (Tomizawa and Casida, 2005).
- Acetamiprid induces lower oxidative stress, while Thiamethoxam disrupts microbiota and increases neuroinflammation similarly to IMI (Zhao et *al.,* 2020).

Table 3: Comparison of neonicotinoid pesticides' effects on gut microbiota and neurological health

Factor	Imidacloprid (IMI)	Thiamethoxam	Clothianidin
Microbiota Disruption	Severe	Moderate	Mild
Neuroinflammatory Effects	High	Medium	Low
Oxidative Stress Induction	High	Relatively Low	Mild
Tissue Retention Duration	Long	Medium	Short
Brain Accumulation	High	Moderate	Low

This comparison highlights IMI as the most hazardous neonicotinoid in terms of microbiota disruption, neuroinflammation, and oxidative stress, making it more strongly linked to chronic neurological disorders than other compounds in its class.

8. TECHNIQUES FOR ANALYZING IMI'S IMPACT ON NEUROMICROBIOTA

8.1 16S rRNA Sequencing for Microbiota Analysis

16S rRNA gene sequencing is widely used to investigate IMI's impact on neuromicrobiota composition. This technique involves extracting ribosomal RNA (rRNA) genes from fecal or intestinal tissue samples and conducting high-throughput sequencing to identify bacterial species and track microbiota changes after pesticide exposure.

8.2 Mass Spectrometry (LC-MS/MS) for SCFA Analysis

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is employed to detect alterations in SCFA levels due to IMI exposure, helping researchers understand the compound's effects on microbiota metabolism and

brain function. Studies have shown that IMI-exposed rodents experience a marked decline in butyrate and propionate levels, further confirming the pesticide's role in gut-brain axis dysregulation (Shoubridge et *al*., 2021).

8.3 RNA-Seq for Neuroinflammatory Gene Expression Analysis

RNA sequencing (RNA-Seq) is used to examine gene expression in the gut and brain following IMI exposure. This technique provides in-depth insights into how IMI affects molecular pathways linked to neuroinflammation, SCFA metabolism, and neurotransmitter production. One study found that IMI exposure led to an upregulation of inflammatory genes such as IL-1β and TNF-α, indicating that the pesticide directly triggers neuroinflammatory processes via gut-brain interactions (Wang et *al*., 2022).

9. POTENTIAL THERAPEUTIC STRATEGIES

9.1 Melissa *officinalis* L. as an Antioxidant and Anti-Inflammatory Agent

Extracts of Melissa *officinalis* exhibit potent antioxidant and anti-inflammatory properties, containing bioactive compounds such as:

- **Rosmarinic acid**, which reduces neuroinflammation by inhibiting NF-κB signaling.
- **Flavonoids**, which enhance antioxidant enzyme activity (SOD, GPx) and mitigate oxidative stress.
- **Terpenes**, which regulate neurotransmitter levels and promote brain health.

Experimental studies indicate that administering Melissa *officinalis* extract to IMI-exposed rodents helped restore microbiota balance and reduce neuroinflammation, supporting its potential as a protective intervention.

9.2 Probiotic Therapy to Restore Microbiota Equilibrium

Certain probiotic strains, such as Lactobacillus rhamnosus and Bifidobacterium longum, have demonstrated neuroprotective properties by modulating gut microbiota composition, reducing neuroinflammation, and enhancing SCFA production. These probiotics could serve as potential

therapeutic agents against IMI-induced neurotoxicity by restoring gut homeostasis and mitigating cognitive impairments.

Given its profound impact on the gut-brain axis, oxidative stress, and neuroinflammation, IMI represents a significant neurological and environmental health risk. Further research into microbiota-targeted interventions, including probiotics and plant-based therapies, could offer promising avenues to counteract its detrimental effects and protect against pesticide-induced cognitive decline.

CONCLUSION

This study highlights the chronic neurotoxic effects of Imidacloprid (IMI), particularly its impact on the gut microbiota and nervous system. The findings indicate that IMI significantly disrupts microbial balance in the gut, negatively affecting neurological and behavioral health. Analyses reveal increased oxidative stress, neuroinflammation, and impaired short-chain fatty acid metabolism—factors that may contribute to the long-term development of neurodegenerative disorders such as Alzheimer's and Parkinson's disease.

A comparison with other neonicotinoids, such as Thiamethoxam and Acetamiprid, demonstrates that IMI induces more severe neuroinflammatory and oxidative stress responses, making it one of the most concerning pesticides in terms of environmental and health risks. Additionally, IMI’s effects on the gene expression of neuroinflammatory and neuro-metabolic pathways suggest that it can lead to lasting alterations in brain function.

Despite these negative effects, the study suggests that protective interventions using *Melissa officinalis* extract and probiotics can provide effective neuroprotection. *Melissa officinalis* exhibits potent antioxidant properties, reducing MDA levels and enhancing antioxidant enzyme activity. Meanwhile, probiotics help restore microbial balance and improve SCFA production, leading to beneficial effects on neurological health and cognitive behavior.

REFERENCES

Carabotti, M., Scirocco, A., Maselli, M. A., & Severi, C. (2015). The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Annals of Gastroenterology, 28*(2), 203-209.

Cryan, J. F., O'Riordan, K. J., Cowan, C. S., Sandhu, K. V., Bastiaanssen, T. F., Boehme, M., ... & Dinan, T. G. (2019). The microbiota-gut-brain axis. *Physiological Reviews, 99*(4), 1877-2013.

Duzguner, V., & Erdogan, S. (2010). Acute oxidant and inflammatory effects of imidacloprid on the mammalian central nervous system and liver in rats. *Pesticide Biochemistry and Physiology, 97*(1), 13-18.

Gibbons, D., Morrissey, C., & Mineau, P. (2015). A review of the direct and indirect effects of neonicotinoids and fipronil on vertebrate wildlife. *Environmental Science and Pollution Research, 22*(1), 103-118.

Joly, F., Lambert, C., Payros, D., & Bailly, J. (2021). Pesticides and gut microbiota: A call for research. *Environmental Pollution, 283*, 117074.

Kara, M., Erdoğan, Ş., & Bayram, F. (1983). Protective effect of some medicinal plants against oxidative stress. *Journal of Medicinal Plants Research, 8*(5), 243-251.

Kennedy, D. O., Scholey, A. B., & Wesnes, K. A. (2003). Dose dependent changes in cognitive performance and mood following acute administration of Melissa officinalis (lemon balm). *Phytotherapy Research, 17*(5), 448-453.

Lerner, A., Aminov, R., & Matthias, T. (2017). Dysbiosis may trigger autoimmune diseases via inappropriate post-translational modification of host proteins. *Frontiers in Microbiology,*. *8*(2), 60-75

Li, Y., Zhang, L., Zhang, Y., Yang, J., & Zhang, H. (2020). Effects of neonicotinoid pesticides on gut microbiota and their potential implications for health. *Environmental Pollution, 265*, 114612.

Omar, S. H., Ahmed, Q. U., Al-Wabel, N. A., & Ibrahim, K. E. (2022). Antioxidant and antimicrobial properties of Melissa officinalis L.: A comprehensive review. *Molecules, 27*(2), 520.

Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The central nervous system and the gut microbiome. *Cell, 167*(4), 915-932.

Tomizawa, M., & Casida, J. E. (2005). Neonicotinoid insecticide toxicology: Mechanisms of selective action. *Annual Review of Pharmacology and Toxicology, 45*, 247-268.

Wang, Y. et al. (2022). The role of medicinal plants in gut-brain axis modulation. Phytomedicine, 95, 153796.

Yang, X. et al. (2021). Gut microbiota imbalance induced by pesticide exposure. Environmental Toxicology, 36(7), 982-994.

Zhang, H., Ma, Y., & Zhang, Y. (2020). Effects of neonicotinoids on gut microbiota and potential implications for gut health. *Science of the Total Environment, 721*, 137729.

Zouaoui, S., Rouabhi, R., Taib, C., Bouteraa, Z., Gasmi, S., Benaicha, B., & Toualbia, N. (2024). Impact of Imidacloprid on Forebrain Mitochondrial Enzymatic Activities Ec50, Ic50 and Impacts of Mellissa Extracts, *Journal of Bioresource Management, 11* (2).

CHAPTER 3
BICROBIOTA: UNLOCKING THE SECRETS OF MICROBIAL COMMUNITIES IN HEALTH AND THE ENVIRONMENT

Burhan KHALID[1]
Musrat SHAHEEN[2]

[1] Huazhong Agricultural University, College of Plant Science and Technology, Wuhan, 430070, China, burhankhalid1859@gmail.com
[2] Government College University, Department of Chemistry, Faisalabad 38000, Punjab Pakistan, musarat7734@gmail.com

INTRODUCTION

The microscopic, omnipresent, invisible colonies that underpin life on our planet are the biota. Bacteria, fungi, viruses, and archaea are some of the microbes that make up the biota, but they are no mere tenants, but rather active participants in every ecosystem, nearly every technology, and practically all health issues. Understanding the biota is like discovering an undiscovered territory that contains the solutions to many of the key issues that humanity must solve.

Definition and Scope

Biota are the assemblages of microorganisms that inhabit a defined niche, which themselves form complex ecosystems that interact with their hosts and the environment. According to Qin et al. (2010), and they report that the unique microbial makeup of the human gut microbiota alone contains over 100 trillion microbes, encoding 150 times the genetic diversity of the human genome. These microbial communities not only exist in humans, humans are just one of their environments, but they also live in soil, water, air, and in any man-made environment such as homes and hospitals. Research into the biota extends from its influence on global ecosystems and climate change to its relevance for human health. Marine microbiota is the basis of carbon cycling and soil microbiota are essential to agriculture (Fierer, 2017; Webster & Reusch, 2017).

Historical Background and Discovery

This was thanks to Antonie van Leeuwenhoek and his first microscopic observation of microbes in the 17th century that became the basis on which we learned about our bicrobiota. But the science of microbiology was not formed until the 20th century, by scientists like Louis Pasteur and Robert Koch. According to the Gilbert et al. (2018): “In the last two decades of the twentieth century, the methods for studying microbial diversity revolutionized with genetic sequencing and became longer and more complex designing.” Revolutionary efforts such as the "Human Microbiome Project” have characterized microbial communities inhabiting various sites of the human body and their crucial roles in health and disease (Integrative HMP Research

Network Consortium, 2019). Such discoveries have changed the way we see ourselves, showing that humans are ecosystems full of microorganisms, not just unique individuals.

Importance of Bicrobiota in Modern Science

Microbiota research is changing the face of environmental science, agriculture, and medicine. Increased knowledge of gut microbiota has resulted in advancements in the treatment of illnesses like obesity and irritable bowel syndrome (IBS) (Lynch & Pedersen, 2016). Soil microbiota for more sustainable agriculture and higher crop yields (Fierer, 2017). Bicrobiota provides creative answers to important issues like climate change and antibiotic resistance. As one example, scientists are investigating how microbial communities might break down plastics or sequester carbon as methods for tackling climate change (Richardson et al., 2020). Biobiota represents a keystone of modern research considering its heterogeneous possible uses.

Table 1: Composition of Bicrobiota: Key Microorganisms, Their Roles, and Examples in Various Ecosystems

Microorganism	Description	Role in Bicrobiota	Examples	References
Bacteria	Single-celled prokaryotic organisms, the most abundant members of bicrobiota.	Aid in digestion, nutrient cycling, and immune system modulation.	*Bacteroides* (gut), *Lactobacillus* (gut), *Streptomyces* (soil).	Lynch & Pedersen, 2016; Qin et al., 2010
Fungi	Eukaryotic organisms, including yeasts, molds, and mushrooms.	Decompose organic matter, form symbiotic relationships with plants (mycorrhizae).	Mycorrhizae(soil), *Candida* (human microbiota), *Saccharomyces* (yeast).	Smith & Read, 2008; Fierer, 2017
Viruses	Non-living entities that infect host cells to replicate.	Regulate microbial populations, transfer genetic material	Bacteriophages (infected with bacteria), human gut virome.	Rohwer & Thurber, 2009; Gilbert et al., 2018

		between organisms.		
Archaea	Single-celled prokaryotes, often found in extreme environments.	Contribute to nutrient cycling, methane production, and extreme environment survival.	*Methanobrevibacter* (human gut), *Halobacterium* (salt lakes).	Baker et al., 2020; Mackelprang et al., 2011

1. THE COMPOSITION OF BICROBIOTA

This bicrobiota here's composition is nature's proof of how diverse and adaptable life can be. These microbial communities comprise many interacting species, each contributing in their way to the environment.

1.1 Microbial Diversity: Bacteria, Fungi, Viruses, and Archaea

Each microbe of the cosmobiota performs a unique role. While bacteria reign supreme in these ecosystems, viruses, fungi, and archaea also play a significant role. As an example, soil fungi (e.g., mycorrhizae) help plants grow, and gut bacteria (e.g., Bacteroides and Lactobacillus) help digest (Lynch & Pedersen, 2016). Viruses that are frequently ignored play a key role in the transfer of genetic material and in regulating the sizes of microbial populations (Rohwer & Thurber, 2009). Much less studied than bacteria, archaea also perform important functions in extreme environments (Baker et al., 2020), for instance, the human intestine and hydrothermal vents. These microbes adapt to each other, making complex networks that create life.

1.2 Host-Specific Variations in Bicrobiota

What hosts have is a very different bicrobiota. For instance, human gut microbiota differ from those of animals based on the genetic and dietary differences (Sonnenburg & Sonnenburg, 2019). Bicrobiota: each person has its own unique bicrobiota because individuals differ even in their own microbial communities. For example, an individual in Japan, where seaweed is consumed widely, harbors a gut microbiota that is unimaginably different than a person in the US, where much of the food consumed is processed (Hehemann et al.,

2010). These variations illustrate how bicrobiota are capable of adapting to diverse environments and lifestyles.

1.3 Factors Influencing Bicrobiota Composition

Bicrobiota is affected by environment, nutrition, and genetics. Antibiotics can disrupt gut microbiota homeostasis (David et al., 2014), but a fiber rich diet promotes the growth of beneficial bacteria, including Bifidobacterium. Environmental threats such as pollution and climate change also endanger microbiota, especially in vulnerable ecosystems, like the coral reefs (Webster & Reusch, 2017). For example, increasing ocean temperatures and coral bleaching are disrupting the relationship of the coral holobiont with its microbial partners (Hughes et al., 2018). To preserve the diversity of microbes, and the benefits they provide, we need to understand these processes.

2. THE ROLE OF BICROBIOTA IN HUMAN HEALTH

Microbiota have a great influence on digestion and mental health and play a significant role in human health. Like unsung guardians, these microbial armies toil day and night to help keep us healthy. Microbiota is important for human health and greatly affects digestion and mental health significance. Microbial populations work hard in the background to keep us healthy like invisible guardians.

2.1 Gut-Brain Axis and Neurological Health

The gut-brain axis is a bidirectional communication system between the gut microbiota and the central nervous system. Neurotransmitters that impact mood and behavior, like serotonin, are produced by gut microorganisms (Cryan & Dinan, 2012). Dysbiosis, or microbial imbalance, has been associated with anxiety and depression (Foster & Neufeld, 2013). For instance, the gut microbiota of depressed people is commonly low in Lactobacillus and Bifidobacterium (Jiang et al., 2015). This link highlights the importance of gut health to mental wellness.

2.2 Immune System Modulation

Microbiota are essential for the development and function of the immune system. Gut microbiota, for instance, instruct lymphocytes differentiate pathogenic microbes and innocuous molecules (Belkaid & Hand, 2014). Disruptions in this pathway can cause autoimmune conditions like multiple sclerosis and Crohn's disease. The hygiene hypothesis (Strachan, 1989) suggests that children raised in extremely clean surroundings are more susceptible to allergy and autoimmunity. This is why early microbial exposure is critical for immune function.

2.3 Metabolic Functions and Nutrient Synthesis

Microbiota is important for metabolism through complex carbohydrate degradation, and for vitamin synthesis, e.g. B12 and K. Dysbiosis (when the gut flora is imbalanced) is associated with metabolic diseases, such as type 2 diabetes and obesity (Turnbaugh et al., 2006). For instance, there is, in general, higher Firmicutes to Bacteroidetes ratio in the guts microbiota of obes type individuals (Ley et al 2006). These results indicate that manipulation of microbiota may represent a strategy to treat metabolic disorders.

2.4 Bicrobiota and Chronic Diseases

Dysbiosis (the imbalance of gut microbes) is implicated in the etiology of many chronic diseases including cardiovascular disease and Crohn's disease (Lynch & Pedersen, 2016). These associations could result in potential new interventions, including microbiota-targeted treatment of diabetes and obesity. Fecal microbiota transplantation (FMT), for example, is being investigated for other disorders (e.g., ulcerative colitis) and has shown efficacy for the treatment of Clostridioides difficile infections (Kassam et al., 2013). These data emphasize the role of the bicrobiota as a therapeutic target.

3. BICROBIOTA AND ENVIRONMENTAL INTERACTIONS

Bicrobiota is not only present in our human body; it is involved and plays role as a global game changer; and communicates with ecosystems and environmental processes.

3.1 Bicrobiota in Soil and Agriculture

Microbes in the soil are responsible for The international phenomenon "biobiota" affects ecosystems and environmental processes beyond those of the human body, soil fertility, nutrient cycling, plant health. For example, mycorrhizal fungi establish symbiotic relationships with plant roots to enhance the acquisition of nutrients (Smith & Read, 2008). Sustainable farming practices, such as crop rotation and organic farming, rely on a healthy soil microbiome. Scientists have also considered the role of soil bacteria in enhancing agricultural resilience to climate change (Fierer, 2017). Such uses underscore the important role that the bicrobiota plays in sustaining food security.

3.2 Bicrobiota in Aquatic Ecosystems

The bicrobiota are key players in aquatic biogeochemical cycles providing services like the breakdown of organic materials and the transforming potential of nitrogen. Other examples include coral reefs, whose survival is dependent on their symbiotic microbial residents, especially in nutrient poor environments (Webster & Reusch, 2017). Pollution and climate change, which pose particular threats to these fragile ecosystems, have consequences for marine life. It is thus crucial to protect aquatic bicrobiota to ensure the health of the ecosystem and biodiversity in order to thrive.

3.3 Impact of Climate Change on Bicrobiota

Climate change is altering microbial communities around the world. For example, one of the effects of increasing temperatures is the shift in soil microbiota which consequently affects plant performance and carbon fixation (Classen et al., 2015). Thawing permafrost is releasing ancient bacteria into the ecosystem, with unknown consequences (Mackelprang et al., 2011). As these developments indicate, research is needed to determine how bicrobiota could adapt to and mitigate the effects of climate change.

4. TECHNOLOGICAL ADVANCES IN BICROBIOTA RESEARCH

Technological advances are revolutionising the study of bicrobiota, enabling researchers to interrogate this microscopic world in detail never before possible.

4.1 Genomic Sequencing and Metagenomics

That said, next-generation sequencing and other DNA sequencing-based technologies have transformed insight into the bicrobiota. Initiatives such as the Earth Microbiome Project are cataloging this global microbial diversity (Gilbert et al., 2014). By eliminating the need for culture, metagenomics allows the investigation of entire microbial communities, revealing the vast diversity of unculturable microorganisms (Handelsman, 2004). These resources allowed to understand microbial communities from unprecedented perspectives.

4.2 Artificial Intelligence and Machine Learning in Bicrobiota Analysis

Artificial intelligence is being applied to predict microbial activity and discover patterns in large datasets (Pasolli et al., 2016). For example, machine learning methods can be used to identify microbial signatures associated with diseases such as colorectal cancer (Yu et al., 2017). These tools enable personalized approaches to bicrobiota research and accelerate discoveries.

4.3 Challenges and Ethical Considerations

As research on biota advances, ethical challenges arise. For example, how should microbiological data be utilized and by whom? Such questions are particularly relevant for genetic engineering and tailored treatment (McGuire et al., 2008). For the bicrobiota technology to be applied ethically, those questions need to be answered.

5. APPLICATIONS OF BICROBIOTA IN BIOTECHNOLOGY AND MEDICINE

With these two facts we cannot assume that microbes are only scholastic, we employ research in biotechnology, agriculture, and medicine.

5.1 Probiotics and Prebiotics

Prebiotics are substances that stimulate the growth of probiotics which are living bacteria that contribute health benefits (Hill et al., 2014). Probiotic strains such as Bifidobacterium and Lactobacillus are commonly used to promote gut health, for example. A staple of preventative healthcare, these products are widely available.

5.2 Fecal Microbiota Transplantation (FMT)

FMT involves administering a patient with stool material from a healthy donor in order to restore microbial equilibria (Kassam et al., 2013). It is being studied for a host of conditions, including ulcerative colitis, and is pretty effective at treating Clostridioides difficile infections. That implies bicrobiota might be used to treat complex diseases as a therapy.

5.3 Bicrobiota-Based Therapeutics

Microbiota are being used to develop therapies for autoimmune conditions such as inflammatory bowel disease, cancers, and autism. An example of such new innovations are the design and testing of engineered microorganisms as vehicle for drug delivery [29]. Such advances also serve to restore faith in a medicine of the future for people suffering from diseases that are not curable today.

6. FUTURE DIRECTIONS IN BICROBIOTA RESEARCH

While there are still barriers to be addressed, the future of bicrobiota research is bright.

6.1 Personalized Medicine and Bicrobiota Profiling

Microbiota profiling is enabling personalized medicine, adjusting treatments to patients' distinctive microbial profiles (Zmora et al., 2019). This method has the capability of making healthcare a whole new beast by customizing treatment options to the distinct biology of each person.

6.2 Synthetic Biology and Engineered Microbes

Scientists have designed microbes to produce biofuels, detoxify pollutants, and even combat climate change (Keasling, 2010). These applications demonstrate the versatility of bicrobiota and its potential applications for addressing global challenges.

6.3 Global Collaborations and Research Initiatives

One example is the Global Microbiome Conservancy, which aims to lead international efforts to stimulate research of bicrobiota and solve global problems. What this means in practice is that to reach the full potential of bicrobiota we will need multidisciplinary and international collaborations.

CONCLUSION

Summary of Key Insights

Microbiota, a key aspect of life isn’t only affecting human health but has effects on ecosystems and technology. These microbial populations challenge everything from soil fertility to the gut-brain axis.

The Road Ahead: Challenges and Opportunities

As we continue to explore this microscopic universe, there are so many opportunities available to us, but also so many challenges. The innovative and cross-functional collaboration will allow us to unlock the full power of bicrobiota for building a more sustainable and healthful world.

REFERENCES

Baker, B. J., et al. (2020). Diversity, ecology, and evolution of Archaea. *Nature Microbiology, 5*(7), 887–900. https://doi.org/10.1038/s41564-020-0715-z

Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. *Cell, 157*(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience, 13*(10), 701–712. https://doi.org/10.1038/nrn3346

David, L. A., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature, 505*(7484), 559–563. https://doi.org/10.1038/nature12820

Fierer, N. (2017). Embracing the unknown: Disentangling the complexities of the soil microbiome. *Nature Reviews Microbiology, 15*(10), 579–590. https://doi.org/10.1038/nrmicro.2017.87

Gilbert, J. A., et al. (2018). Current understanding of the human microbiome. *Nature Medicine, 24*(4), 392–400. https://doi.org/10.1038/nm.4517

Hehemann, J. H., et al. (2010). Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. *Nature, 464*(7290), 908–912. https://doi.org/10.1038/nature08937

Hughes, T. P., et al. (2018). Global warming transforms coral reef assemblages. *Nature, 556*(7702), 492–496. https://doi.org/10.1038/s41586-018-0041-2

Jiang, H., et al. (2015). Altered fecal microbiota composition in patients with major depressive disorder. *Brain, Behavior, and Immunity, 48*, 186–194. https://doi.org/10.1016/j.bbi.2015.03.016

Kassam, Z., et al. (2013). Fecal microbiota transplantation for *Clostridium difficile* infection: Systematic review and meta-analysis. *American Journal of Gastroenterology, 108*(4), 500–508. https://doi.org/10.1038/ajg.2013.59

Keasling, J. D. (2010). Manufacturing molecules through metabolic engineering. *Science, 330*(6009), 1355–1358. https://doi.org/10.1126/science.1193990

Ley, R. E., et al. (2006). Microbial ecology: Human gut microbes associated with obesity. *Nature, 444*(7122), 1022–1023. https://doi.org/10.1038/nature05414

Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. *New England Journal of Medicine, 375*(24), 2369–2379. https://doi.org/10.1056/NEJMra1600266

Mackelprang, R., et al. (2011). Metagenomic analysis of a permafrost microbial community reveals a rapid response to thaw. *Nature, 480*(7377), 368–371. https://doi.org/10.1038/nature10576

Qin, J., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature, 464*(7285), 59–65. https://doi.org/10.1038/nature08821

Rohwer, F., & Thurber, R. V. (2009). Viruses manipulate the marine environment. *Nature, 459*(7244), 207–212. https://doi.org/10.1038/nature08060

Turnbaugh, P. J., et al. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature, 444*(7122), 1027–1031. https://doi.org/10.1038/nature05414

Webster, N. S., & Reusch, T. B. (2017). Microbial contributions to the persistence of coral reefs. *ISME Journal, 11*(11), 2167–2174. https://doi.org/10.1038/ismej.2017.66

CHAPTER 4
THE DYNAMICS OF GUT MİCROBIOME DYSBIOSIS IN THE DEVELOPMENT & PROGRESSION OF DIABETES MELLITUS

Humaira MUZAFFAR[1]
Sidra ALTAF[2]
Ghulam HUSSAIN[1]
Arslan IFTIKHAR[1]
Imran MUKHTAR[1]
Misbah BATOOL[1]
Maham FATIMA[1]
Asma HUSSAIN[1]
Haseeb ANWAR[1]

[1]Government College University Faisalabad, Department of Physiology, Pakistan, drhumairmuzaffar@gcuf.edu.pk
[2] University of Agriculture Faisalabad, Department of Pharmacy, Pakistan

INTROUCTION

The microbial community in the human gut plays a role in the balance between health and sickness. The microbiota is a collection of bacteria that live inside the body, and the microbiome is the collection of their genomes. Almost 100 trillion germs and over 1000 distinct bacterial species live in the human intestine [1]

The disruption of the microbiome has been linked to serious host diseases like metabolic disorders, cancer, and inflammatory bowel disease [2]. Current findings have started to investigate the gut microbiome's species diversity within and across individuals using metagenomic analysis and 16s ribosomal-RNA gene sequencing [3]. (*Bacteroides*, *Clostridium*, *Fusobacterium*, *Eubacterium*, *Ruminococcus*, *Peptococcus*, *Peptostreptococcus* and *Bifidobacterium* are some of the most common bacteria found in human intestines [4]. Other genera, such as *Escherichia coli* and *Lactobacillus*, are found in the gut, but to a lesser extent. Because many species cannot be cultivated *in vitro*, plenty has still not been identified.

Several endogenous and exogenous factors influence and determine the composition of gut flora, such as diet, genetics, age, geographic origin, and the use of prebiotics and antibiotics. In addition, antibiotics might change the gut microbiota either in a murine model or in a septic patient, leading to immune system alteration[5]

1. GUT BACTERIA'S IMPACT ON HEALTH

Numerous approaches indicate that gut flora is crucial to human health. For instance, gut bacteria can strengthen the immune system, stop the growth of dangerous bacteria, maintain epithelial integrity, control gut growth, and influence neurological development[6]

Gut bacteria are believed to be essential for maintaining epithelial through controlling tight junction permeability. *Lactobacillus plantarum*, for example, has been demonstrated to maintain tight-junction proteins to shield the epithelium barrier from chemical injury [7]. Gastrointestinal diseases such as cramps, abdominal bloating, excessive gas, and dietary allergies can be brought by gut bacteria, bacterial toxins, improperly processed lipids, proteins, and wastes that can pass through the epithelium and enter the bloodstream. Such

symptoms and indicators are typical of the intestinal hyper-permeability that characterizes the leaky gut disease.

Short-chain fatty acids (SCFAs) generated from commensal bacteria have been identified as epithelial barrier function modulators in a recent mice study [8]. The SCFAs generated from bacterial metabolism, notably butyrate, boost intracellular oxygen consumption, resulting in the stability of the HIF-1(transcription factor) and elevating the epithelial coherence in the colon. Colonizing gut bacteria are recognized to be important for the appropriate development of host defense. Lymphopenia of lymphoid structures, low immunoglobulin concentrations, reduced leukocyte pool of bone marrow and abnormal adaptive and innate immunological activities have all been seen in germ-free mice. The offspring's immune system is influenced by maternal microflora[9]. As a result, both the innate and adaptive immune systems and the commensal microbiota have evolved in tandem. The immune system, in particular, plays a crucial role in keeping the microbes safe in the lumen of the gut, and bacterial signaling fundamentally dictates the immune system's development and functional integrity [9]. Two studies [10],[11] used an animal model to demonstrate how peripheral regulatory cell development can be triggered by gut bacterial metabolites like butyrate, which can assist to balance anti and pro-inflammatory responses. Furthermore, commensal bacteria can prevent the growth of harmful bacteria by competing with them for space and resources in the intestinal mucosa, or by creating poisonous metabolites such as acids bacteriocins, and phenols[12]

Gut bacteria also help the host in other ways by modulating gut function, generating vitamins and modulating the growth and function of microglia in the central nervous system[13].Normal CNS development requires a healthy gut microbiome. In general, most problems in CNS growth are associated with a lack of gut flora[14]. Recent research suggests that gut microbiota has an impact on CNS function, development, and gut dysbiosis is linked to neuronal issues[15]. In conclusion, commensal bacteria play various significant functions in human health maintenance, as well as influencing a wide range of complex behaviors, such as emotional, social, and anxiety-like patterns of behavior leading to brain development and function.

2. HEALTHY MICROBIOME

The majority of the bacteria in the human gut flora belong to the phyla *Bacteroidetes* and *Firmicutes*. About 155 bacterial species and 2 archaeal species were found in healthy samples. In the healthy human gut microbiota *Bacteroidetes*, there are eight phyla, 18 families, 23 classes, 38 orders, 59 genera, and 109 species. The bulk of bacterial species are represented by the groups Firmicutes and Actinobacteria, which include 63 (40%), 32 (20%), and 31 (19.7%) members, respectively. The most prevalent grouping of Firmicutes is Clostridia (20.3%), which also includes Bacteroides (18.5%), Bifidobacteriales (16.6%), Enterobacterales (14%), and Lactobacillales (14%). The most common orders are Clostridiales, which includes all of the Clostridia present in the samples, and Bacteroidales, which includes all of the Bacteroidia. 27 organisms comprise the Bifidobacteriaceae family, and 26 of belongings to Bifidobacterium long, which is the most prevalent species[16]

Table1. Gut bacteria's impact on health

Organism	**Effect on the human gastrointestinal tract**
Bacteroides dorei	Promote the regular physiology and activities of the intestine.
Bacteroides fragilis	defends from experimental colitis brought by a commensal bacterium[*Helicobacter hepaticus*)which has the potential to harm
Bacteroides vulgatus	Membrane transport, polysaccharide metabolism, environmental sensing and, gene regulation
Bacteroides thetaiotaomicron	Absorption and breakdown of polysaccharides, production of capsular polysaccharides, environmental sensing, and signal transmission
Bacteroides cellulosilyticus	Complex molecules, such as cellulose, are degraded.

3. GUT BACTERIA'S IMPACT ON DISEASES

GI illnesses[2], obesity[17], cardiovascular diseases [18], allergies [19], and CNS-related diseases [20] were all associated to dysregulation of the gut microbes. In addition, gut microbiome changes might affect mood and behavior[21]. Clinical trials and experiments for the treatment of all these abnormalities can possibly be treated for diseases in humans by altering the composition of the gut flora. About three million people in the US suffer from inflammatory bowel disease (IBD), a group of inflammatory illnesses [22]. Crohn's disease (CD) and Ulcerative colitis (UC) are two basic kinds of IBD, both are linked to gut microbial dysbiosis [23]. By analyzing the common microflora in CD victims and family members, one study revealed five dysbiotic bacterial species[24]. Recent clinical investigations using fecal microbiota transplantation (FMT) to treat the UC have shown that it can significantly change the microbiota formulation, resulting in a microflora formulation that is nearly identical to that of the donor in a victim who gets effective treatment. In the process of checkup treatment, there are no serious unfavorable or side effects [25]. Transplanting the gut microbiota of lean and obese twins into germ-free (GF) mice gave proof that the gut microflora control metabolism to regulate body weight. Mice given fecal microbiomes from obese siblings demonstrated higher total and fat content as well as metabolic traits related to obesity, which weren't seen in mice provided fecal microbiota from lean siblings [26]. T2D is a metabolic condition caused by insulin resistance caused by fat. T2D patients have been found to have dysbiosis of the gut microbiota, although it is still unknown what molecular and cellular processes underlie these symptoms [27]. As it becomes increasingly clear that changes in the variety and composition of the gut microbiota significantly affect the pathogensis of pathogenesise, interest in microbiota-based treatments, such as probiotics, prebiotics, and fecal microbiota transplants, is developing[28]. Treatment with Bacteroides fragilis, for example, has been shown to restore of cytokine and tight junction protein levels in mice with neurological issues resembling autism spectrum disorder (ASD)[29]. It was recently discovered that supplementing with *Lactobacillus helveticus* NS8 could considerably lessen the cognitive, behavioral and biochemical problems brought on by prolonged chronic exposure in children and rats. Such results validate and

support the idea that probiotic supplement may be an effective and secure therapy for mental and behavioral problems[30]

Table 2. Gut bacteria's impact on disease

Organism	Effect on the human gastrointestinal tract
Escherichia coli	Although E. coli is often thought to be a safe gut dweller, pathogenic strains can cause a variety of health concerns, including Crohn's disease and ulcerative colitis.
Bacteroides ovatus	It's possible that it's to account for the onset of intestinal inflammation.
Odoribacter splanchnicus	Involve in utyrate synthesis, tryptophan metabolism, and gelatin hydrolysis. Odoribacter sp. extinction As a result of the lower availability of SCFA, the host becomes inflamed.

4. THE ROLE OF GUT MICROBIOTA IN PANCREATIC DISEASE

On a complex biological assembly process, pancreatic beta cells secrete insulin, but the degree to which the microbiome is involved is unknown. It turns out that bacterial cell membrane segments generated in the gut lumen by proteolytic enzymes are required to maintain the mechanism working, regulating glucose transport and glucose metabolism via the peptidoglycan receptor Nod1 in beta cells.

Insulin is secreted in response to higher sugar concentration post diets to aid protein absorption and glycogen stores. Insulin is produced in epithelial beta cells by sequential synthesis of preproinsulin, a single polypeptide strand that is transcribed and transformed to proinsulin on the rough endoplasmatic reticulum adjacent to the nucleus. Proinsulin is still classified into granulosa cells, also termed as high-density compartments, in the pericellular location, the golgi network's membranes and vesicles (DCVs). Then the DCVs move along microtubules as they mature through the cytoplasm via compartment union, carrier preparation, and proinsulin transformation to insulin when ultimately enter the plasma membrane's proximity. The ductless vesicles can now join with

the membrane and secrete insulin in a dose-dependent manner with respect to blood sugar [31].

A major metabolic imbalance is linked to pancreatic diseases[1]. A pancreatic inflammatory condition called chronic pancreatitis is marked by incurable structural alterations that result in exocrine or endocrine dysfunction and severe pain. According to the necrosis-fibrosis hypothesis, an acute inflammatory process has an immediate impact and leads to chronic irreparable damage as a consequence of recurring acute infections[32]. Despite the fact that drinking alcohol has long been thought to be the biggest contributor to the onset of CP, just 3% of alcoholics get the condition[33]. As a result, additional variables or the initial conditions may be crucial.

Small intestinal bacterial overgrowth (SIBO) is connected to chronic intestinal symptoms like stomach pain, bloating, diarrhea, and dehydration, and it affects 3-92% of CP patients [34]. This problem could be linked to a dysbiosis of the gut microbiota in CP patients, but more research is required. PDC is among the most dangerous cancers. It is still a fatal disease in the majority of cases, and it is Europe's fourth-biggest cause of cancer mortality. Poor results are mostly caused by the fact that the majority of victims present with advanced illnesses. Other variables, including as its aggressive biology, resistance to standard and specific therapy drugs, and a shortage of biomarkers for early identification, compound this. Smoking, obesity, nutrition, genetics, and chronic pancreatic are a few of the recognized risk factors [35]. The correlation between CP (chronic pancreatitis) and PDC (pancreatic ductal cancer) raises the fact that inflammation contributes to the start or encouragement of the mutagenesis process [36].

Changes in the composition of the gut microbes are linked to the onset of a variety of diseases, whereas microbial consistency is linked to good health [37]. Several factors affect the gut microbiome including parameters such as nutrition, age, environment, and antibiotics. Consequently, studies in this field may result in novel therapeutic options such as probiotics, focused antibiotics, dietary modifications, and fecal microbiota transplantation (FMT). Fecal microbiota transplantation (FMT) showing promise as a treatment for IBD [38], and has already been proven beneficial in the management of recurrent/resistant Clostridium Difficile infections[39]. Therefore, identifying a causal

relationship between microbiome imbalance and pancreatic diseases could result in the creation of therapeutic preventative interventions for conditions like CP (chronic pancreatic) and PDC (pancreatic ductal cancer). The intestinal microbiome is often assessed through DNA-based analysis of oral, intestinal, or fecal specimens, as well as particular antibodies against recognized microorganisms [35].

5. RELATION OF GUT MICROBIOTA TO DIABETES

Diabetes Mellitus(DM) is a category of metabolic illnesses defined by elevated glucose level due to insulin insufficiency, either directly or indirectly. The islets that produce insulin degrade and eventually die as a result of type 1 diabetes, an autoimmune disease wherein antibodies are made to a variety of pancreatic-cell components [40]. Insulin resistance (IR), which generates a rising demand for insulin in peripheral tissues and, results in -cells' functional failure, produces type 2 diabetes (T2D) [41]. According to the International Diabetes Federation(IDF) by 2045, there will be 700 million diabetics, up from the predicted 463 million in 2019[42]. This enormous population in danger of diabetes highlights the requirement for a better understanding of the pathogenesis of the disease, which could result in the creation of fresh treatments meant to prevent or delay the progression of the condition.

6. THE GUT MICROBIOTA DYSBIOSIS AND TYPE 1 DIABETES

It is said that Type 1 Diabetes is a pro-inflammatory cell-mediated condition that is triggered by both adaptive and innate immune systems[43]. The main contributors to a genetics-describe as susceptibility to type 1 diabetes include particular human leukocyte antigen genotypes like as DQ8, DQ2, DR4, and some DR3 alleles [44]. Environmental factors, such as how people are fed, what they eat, and whether they were exposed to viruses as children, all have a role in illness onset [45]. Moreover, the pathophysiology of insulin failure and T1D may be linked to changes in gut microbiota makeup [46]. Despite this, the majority of studies looking into the idea that gut microbiota plays a role in T1D pathogenesis are conducted on mouse models, with a lack of studies on humans to support it.

Earlier life is characterized by immune system development, gut microbiota maturation, and the emergence of the primary autoantibodies associated with T1D [30]. Breastfeeding, diet, delivery route, antibiotic usage, and interaction to bacteria in the environment are all elements that have the potential to alter the structure of the gut microbes [47], [48]. Their actions can cause intestinal barrier disturbance and delayed immune response development, which can predispose to T1D development in later life [49]. Furthermore, the host's genetic makeup can react with the gut microbiota, resulting in alterations in microbial makeup, immunological functions, and vulnerability to Type 1 diabetes. [50], [51].

Dysbiosis, which is defined as a persistent or repeated departure from normal microbial equilibrium, can lead to the self-tolerance decline as well as the development of effector cells and proinflammatory chemicals throughout the body. These events are all linked to the gastrointestinal wall's enhanced permeability, the movement of bacterial matter through the epithelium membrane, and a higher expression of antigens and autoantigens. This causes the activation of the pro-inflammatory cascade in the colon, pancreas, and lymph nodes to become activated [52]. Moreover, in patients with T1D, the pancreas' exocrine function, mucosal barrier quality, and microvilli attachment are all compromised [53], [54]. Dysbiosis-induced intestinal inflammation and a decrease in SCFAs may contribute to the development of Type 1 Diabetes [55]. Butyrate also inhibits bacterial movement via epithelial cells and has anti-inflammatory effects [56]. A butyrate diet increased the number and activity of regulatory T cells, whereas butyrate-yielding diets and acetate reduced serum levels of diabetogenic agents including Interleukin-21, and improved intestinal health [57]. In non-obese diabetic (NOD) mice, this sort of diet decreased the prevalence of diabetes. Female non-obese diabetic (NOD) mice also had numerous exocrine islets that were free of invasion [58].

By weakening the intestinal mucosal barrier, changes in intestinal microorganisms can cause fatty acid and lipopolysaccharide (LPS) spillage. Toll-like receptor 4 (TLR4) is activated as a result, resulting in metabolic inflammation [59]. TLRs play a role in dendritic cell development as well as in identifying pathogen-associated molecular patterns in the microbiome [60]. They aid in the protection of the host against pathogenic microorganisms. TLRs

and interleukin 1 are not the only innate immune receptors that MyD88 adapts to. The microbiota in the distal section of the intestine can be altered by a MyD88 deficiency [57]. Furthermore, in NOD mice, knocking down MyD88 shielded them from developing T1D [58]. LPS is a bacterial endotoxin that is found in Gram-negative bacteria's outer membrane and is thought to represent a biological connection between inflammation, gut microbiota, and T1D [47]. Compared to those without diabetes, patients with T1D had greater proportions of circulatory LPS, according to a case-control study [61].

Therefore, determining if the microbial change is causal or consequential for T1D development is problematic. Figure 2 depicts the potential impact of dysbiosis on T1D progression. The majority of current research focuses on the role of gut microbiota in the cell autoimmunity process rather than on whether gut microbiota activates T1D.



Figure 1. The potential impact of dysbiosis on the onset of type 1 diabetes. This diagram is modified from [62]

7. GUT MICROBIOTA DYSBIOSIS & TYPE 2 DIABETES

The primary reason for Type 2 Diabetes is inadequate insulin production by pancreatic cells and a condition known as "insulin resistance," This is the inability of tissues that are sensitive to insulin to react adequately to insulin [63]. Insulin secretion is reduced when -cells are dysfunctional, resulting in higher glucose levels in the blood. IR elevates glycemia via stimulating glucose

synthesis in the liver and impairing the absorption of glucose in the muscle, liver, and adipose tissue. Chronic hyperglycemia develops as a result of this scenario, damaging many tissues and organs and causing harmful macro and micro plays a role in vascular problems [64]. Low-grade chronic inflammation participates in the progression of insulin resistance (IR), as a result, T2D[65]. A family history of diabetes, genetic predisposition, and ethnicity, as well as environmental and metabolic factors such as diet, obesity, and low-grade physical activity, are all possible factors for T2D. One of the most significant risk factors is obesity, as it is linked to metabolic alterations that contribute to IR [66]. Our understanding of the significance of intestinal microbiota is largely based on research using germ-free animals, who can be exposed to particular germs during study but are born and raised without exposure to germs. [67] found that diet-induced obesity is resistant to these animals, and that subjected to Enterobacter cloacae, obesity-related bacteria, or bacteria acquired from obese donors causes greater energy harvesting capacity, impaired glucose tolerance and weight gain [68]. These findings point to a possible link between obesity and intestinal microbiota.

Type 2 diabetes is marked by a reduction in butyrate synthesis, one of the SCFAs that promotes the correct activity of -cells in the pancreas, particularly after food intake[69]. Butyrate aids in the regulation of immune system processes and the defense against invading pathogens [70]. It influences the functioning of gut macrophages inhibits the development of interleukin-6 (IL-6),interleukin-12 (IL-12), two pro-inflammatory cytokines, and nitric oxide, and encourages regulatory T cell differentiation, all of which are triggered by LPSs [71]. It also stimulates intestinal gluconeogenesis, which has a positive impact on glucose homeostasis [72]. Sanna et al. discovered that abnormalities in propionate formation or absorption are associated with a greater risk of T2D and the host has a genetically driven boost in gut butyrate synthesis is linked to a better action of insulin following an oral glucose test. Low-grade inflammation arises as a result of this condition[73],[74].

TLR4 is a pattern-recognition receptor belongs to the toll-like receptor family, which play a role in the synthesis of cytokine and its release in bacterial pathogen as well as stimulation of the pro-inflammatory signaling pathway [75], [76]. Free fatty acids may impact adipocytes and macrophages and via

TLR4, according to in vivo and in vitro studies it causes inflammation. They can thereby alter glucose homeostasis suppressing insulin signaling through the phosphorylation of serine on insulin receptor substrate 1 (IRS-1) [75], [77]. This IRS-1 alteration is regarded as an IR status indicator [78].

Furthermore, metabolism endotoxemia has been linked to inflammatory tone dysregulation, body weight increase, and diabetes [79]. Because of their potential to change intestine leakage, it is possible for gut flora to change the condition of endotoxemia and inflammation [80]. Endotoxemia is becoming more visible in obesity and T2D, although human studies showing increased intestinal permeability and altered tight junction expression are still lacking. Figure 1 depicts the potential impact of dysbiosis on the progression of T2D.



Figure 2. The potential impact of dysbiosis on the onset of type 2 diabetes [44]

CONCLUSION

The gut microbiota plays an important role in animal development and adult organismal homeostasis. Changes in gut microbial composition have been linked to a variety of chronic disorders, including both physiological and psychological diseases, according to a large body of evidence. One of the most common metabolic diseases is diabetes, with serious implications and problems. An essential component of human health is the intestinal microbiome and it's crucial to comprehend its importance in the functioning of living

creatures. It is critical to determine whether or not there is a causal association between the development of diabetes and gut microorganisms. Further study, specifically merged researchs that can reveal how the microbiome influence or affects the host, is necessary to maximize the potential of the gut flora.

REFERENCES

1. Leal-Lopes C, Velloso FJ, Campopiano JC, Sogayar MC, Correa RG. Roles of commensal microbiota in pancreas homeostasis and pancreatic pathologies. Journal of Diabetes Research. 2015;2015.
2. Constante M, Fragoso G, Lupien-Meilleur J, Calvé A, Santos MM. Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis. Inflammatory bowel diseases. 2017;23(5):753-66.
3. Gill SR, Pop M, DeBoy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. science. 2006;312(5778):1355-9.
4. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. science. 2005;308(5728):1635-8.
5. Guarner F, Malagelada J-R. Gut flora in health and disease. The lancet. 2003;361(9356):512-9.
6. Ahern PP, Faith JJ, Gordon JI. Mining the human gut microbiota for effector strains that shape the immune system. Immunity. 2014;40(6):815-23.
7. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer R-JM, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2010;298(6):G851-G9.
8. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell host & microbe. 2015;17(5):662-71.
9. Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, et al. The maternal microbiota drives early postnatal innate immune development. Science. 2016;351(6279):1296-302.
10. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-50.

11. Arpaia N, Campbell C, Fan X, Dikiy S, Van Der Veeken J, Deroos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451-5.
12. Stecher B, Hardt W-D. The role of microbiota in infectious disease. Trends in microbiology. 2008;16(3):107-14.
13. Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nature neuroscience. 2015;18(7):965-77.
14. Mangalam A, Shahi SK, Luckey D, Karau M, Marietta E, Luo N, et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell reports. 2017;20(6):1269-77.
15. Principi N, Esposito S. Gut microbiota and central nervous system development. Journal of Infection. 2016;73(6):536-46.
16. King CH, Desai H, Sylvetsky AC, LoTempio J, Ayanyan S, Carrie J, et al. Baseline human gut microbiota profile in healthy people and standard reporting template. PloS one. 2019;14(9):e0206484.
17. Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. The Journal of nutrition. 2017;147(7):1468S-75S.
18. Zeisel SH, Warrier M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. Annual review of nutrition. 2017;37:157-81.
19. Knaysi G, Smith AR, Wilson JM, Wisniewski JA. The skin as a route of allergen exposure: part II. Allergens and role of the microbiome and environmental exposures. Current allergy and asthma reports. 2017;17(1):1-8.
20. Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: a review. Annals of neurology. 2017;81(3):369-82.
21. Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system. Cell metabolism. 2017;26(1):110-30.
22. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged≥ 18 years—United States, 2015. Morbidity and mortality weekly report. 2016;65(42):1166-9.

23. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119-24.
24. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut. 2011;60(5):631-7.
25. Wu J, Ji A, Wang X, Zhu Y, Yu Y, Lin Y, et al. MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells. Journal of translational medicine. 2015;13(1):1-15.
26. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1241214.
27. Larsen N, Vogensen FK, Van Den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS one. 2010;5(2):e9085.
28. Lee SH, Claire B. Gut microbiome-brain communications regulate host physiology and behavior. J Nutr. 2015;2.
29. Doenyas C. Gut microbiota, inflammation, and probiotics on neural development in autism spectrum disorder. Neuroscience. 2018;374:271-86.
30. Liang S, Wang T, Hu X, Luo J, Li W, Wu X, et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015;310:561-77.
31. Stojanović O, Trajkovski M. Microbiota guides insulin trafficking in beta cells. Cell Research. 2019;29(8):603-4.
32. Sarner M, Cotton P. Classification of pancreatitis. Gut. 1984;25(7):756-9.
33. Vonlaufen A, Spahr L, Apte MV, Frossard J-L. Alcoholic pancreatitis: A tale of spirits and bacteria. World Journal of Gastrointestinal Pathophysiology. 2014;5(2):82.
34. Kim DB, Paik C-N, Sung HJ, Chung WC, Lee K-M, Yang J-M, et al. Breath hydrogen and methane are associated with intestinal symptoms in patients with chronic pancreatitis. Pancreatology. 2015;15(5):514-8.

35. Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. British Journal of Nutrition. 2014;111(3):387-402.
36. Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61(4):582-8.
37. Milani C, Ferrario C, Turroni F, Duranti S, Mangifesta M, Van Sinderen D, et al. The human gut microbiota and its interactive connections to diet. Journal of Human Nutrition and Dietetics. 2016;29(5):539-46.
38. Sheehan D, Moran C, Shanahan F. The microbiota in inflammatory bowel disease. Journal of gastroenterology. 2015;50(5):495-507.
39. Kelly CR, Khoruts A, Staley C, Sadowsky MJ, Abd M, Alani M, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Annals of internal medicine. 2016;165(9):609-16.
40. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293-300.
41. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet. 2014;383(9922):1068-83.
42. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice. 2019;157:107843.
43. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert review of endocrinology & metabolism. 2010;5(1):19-28.
44. Hu Y, Wong FS, Wen L. Antibiotics, gut microbiota, environment in early life and type 1 diabetes. Pharmacological research. 2017;119:219-26.
45. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. The Lancet. 2016;387(10035):2340-8.
46. Bachem A, Makhlouf C, Binger KJ, de Souza DP, Tull D, Hochheiser K, et al. Microbiota-derived short-chain fatty acids promote the memory

potential of antigen-activated CD8+ T cells. Immunity. 2019;51(2):285-97. e5.
47. Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiology and molecular biology reviews. 2017;81(4):e00036-17.
48. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature. 2014;509(7500):357-60.
49. Zhou H, Sun L, Zhang S, Zhao X, Gang X, Wang G. The crucial role of early-life gut microbiota in the development of type 1 diabetes. Acta Diabetologica. 2021;58:249-65.
50. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, et al. The effect of host genetics on the gut microbiome. Nature genetics. 2016;48(11):1407-12.
51. Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes. 2015;64(10):3510-20.
52. Pellegrini S, Sordi V, Bolla AM, Saita D, Ferrarese R, Canducci F, et al. Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota. The Journal of Clinical Endocrinology & Metabolism. 2017;102(5):1468-77.
53. Pinto E, Anselmo M, Calha M, Bottrill A, Duarte I, Andrew PW, et al. The intestinal proteome of diabetic and control children is enriched with different microbial and host proteins. Microbiology. 2017;163(2):161-74.
54. Gavin PG, Mullaney JA, Loo D, Cao K-AL, Gottlieb PA, Hill MM, et al. Intestinal metaproteomics reveals host-microbiota interactions in subjects at risk for type 1 diabetes. Diabetes Care. 2018;41(10):2178-86.
55. Ma Q, Li Y, Wang J, Li P, Duan Y, Dai H, et al. Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing. Biomedicine & Pharmacotherapy. 2020;124:109873.

56. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS microbiology letters. 2009;294(1):1-8.
57. Li W-Z, Stirling K, Yang J-J, Zhang L. Gut microbiota and diabetes: From correlation to causality and mechanism. World journal of diabetes. 2020;11(7):293.
58. Mariño E, Richards JL, McLeod KH, Stanley D, Yap YA, Knight J, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nature immunology. 2017;18(5):552-62.
59. Velloso LA, Folli F, Saad MJ. TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocrine reviews. 2015;36(3):245-71.
60. Li J, Wang X, Zhang F, Yin H. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases. Pharmacology & therapeutics. 2013;138(3):441-51.
61. Devaraj S, Dasu M, Park S, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009;52:1665-8.
62. Bielka W, Przezak A, Pawlik A. The role of the gut microbiota in the pathogenesis of diabetes. International Journal of Molecular Sciences. 2022;23(1):480.
63. Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51-60.
64. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
65. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annual review of immunology. 2011;29(1):415-45.
66. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma Y-Z, et al. Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 2002;51(4):1022-7.
67. Rabot S, Membrez M, Bruneau A, Gérard P, Harach T, Moser M, et al. Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin

resistance and have altered cholesterol metabolism. The FASEB Journal. 2010;24(12):4948-59.
68. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. nature. 2006;444(7122):1027-31.
69. Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nature genetics. 2019;51(4):600-5.
70. Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. Journal of clinical gastroenterology. 2011;45:S120-S7.
71. Wang H, Hou L, Kwak D, Fassett J, Xu X, Chen A, et al. Increasing regulatory T cells with interleukin-2 and interleukin-2 antibody complexes attenuates lung inflammation and heart failure progression. Hypertension. 2016;68(1):114-22.
72. De Vadder F. Kovatcheva-Datchary P Zitoun C, Duchampt A, Backhed F, Mithieux G. Microbiota-Produced Succinate Improves Glucose Homeostasis via Intestinal Gluconeogenesis. Koval M, ed. Cell Metab. 2016;24(1):151-7.
73. Cunningham A, Stephens J, Harris D. Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathogens. 2021;13(1):1-13.
74. van den Munckhof IC, Kurilshikov A, ter Horst R, Riksen NP, Joosten L, Zhernakova A, et al. Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obesity Reviews. 2018;19(12):1719-34.
75. Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology. 2001;1(2):135-45.
76. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nature Reviews Immunology. 2009;9(10):692-703.
77. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. The Journal of clinical investigation. 1997;100(9):2158-69.

78. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852-71.
79. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-72.
80. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-81.

CHAPTER 5
THE DYNAMIC INTERPLAY BETWEEN MICROBIOMES, HUMAN HEALTH AND DISEASES: INSIGHTS INTO INTERACTION MECHANISMS AND THERAPEUTIC IMPLICATIONS

Aminu Ibrahim BELLO[1]
Yahaya Riko YUNUSA[2]
Salihu SALISU[3]
Assoc. Prof. Dr. Bashir ABDULKADIR[4]

[1] Umaru Musa Yar'adua Unıversıty, Faculty of Natural and Applıed Scıences, Department of Mıcrobıology, Katsına, Nıgerıa, aminubello0906@gmail.com, 0009-0009-4805-9574
[2] Umaru Musa Yar'adua Unıversıty, Faculty of Natural and Applıed Scıences, Department of Mıcrobıology, Katsına, Nıgerıa, yahaya.yunusa@umyu.edu.ng, 0000-0001-9209-7468
[3] Umaru Musa Yar'adua Unıversıty, Faculty of Natural and Applıed Scıences, Department of Mıcrobıology, Katsına, Nıgerıa, mcb210944@students.umyu.edu.ng, 0009-0000-5340-850X
[4] Umaru Musa Yar'adua Unıversıty, College of Health Sciences, Department of Medical Laboratory Science, Nıgerıa, bashir.abdulkadir@umyu.edu.ng, 0000-0001-8616-6615

INTRODUCTION

The human microbiome is a complex and dynamic ecosystem that plays a crucial role in maintaining health and influencing disease susceptibility. This vast community of microorganisms, including bacteria, viruses, fungi, and archaea, is found in various locations of the human body such as the gut, skin, oral cavity, and respiratory tract. The gut microbiome, in particular, has garnered significant attention due to its involvement in digestion, immune modulation, and metabolic functions (Ogunrinola et al., 2020).

Since disruptions in microbial balance, known as dysbiosis, have been linked to numerous health conditions, including inflammatory bowel disease (IBD), obesity, diabetes, and even neurological disorders such as depression and Alzheimer's disease, understanding the mechanisms by which microbiomes interact with host physiology is critical for developing microbiome-targeted therapies to restore homeostasis and prevent disease progression (Shreiner et al., 2015).

Recent advancements in microbiome research have revealed that microbial communities engage in intricate interactions with the host through metabolic pathways, immune signaling, and cross-kingdom communication (Marchesi & Ravel, 2015). Studies leveraging next-generation sequencing and metabolomics have expanded knowledge of microbial diversity and function, highlighting the microbiome's role in modulating inflammation, drug metabolism, and pathogenic resistance (Gilbert et al., 2016). Furthermore, therapeutic strategies, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), are being explored as potential interventions to restore microbial equilibrium in dysbiotic individuals. By dissecting the interplay between microbiomes, human health, and disease, researchers can uncover novel insights into disease pathogenesis and pave the way for precision medicine approaches (Zmora et al., 2018).

Definition of Microbiomes

Microbiomes refer to the diverse communities of microorganisms, including bacteria, viruses, fungi, and archaea, that inhabit various environments within the human body, such as the gut, skin, oral cavity, and respiratory tract. These microbial ecosystems play a fundamental role in

maintaining homeostasis by regulating metabolic functions, immune responses, and protection against pathogens. The composition and diversity of microbiomes vary based on factors such as genetics, diet, lifestyle, and environmental exposures, influencing overall health and disease susceptibility. Understanding the structure and function of microbiomes is essential for identifying their contributions to human physiology and developing targeted therapeutic strategies (Lloyd-Price et al., 2016).

History of Microbiome Research

Microbiome research can be traced to Antonie van Leeuwenhoek's discovery of microorganisms. A key step in the evolution of the field is the development of germ theory. Subsequent advances in DNA sequencing allowed scientists to study microbial communities more accurately. The Human Microbiome Project, launched in 2007, was another milestone that provided deeper insights into microbial diversity and its role in human health and disease (Proctor, 2016).

Diversity of the Human Microbiome

The human microbiome consists of diverse microbial communities that vary by body site and individual factors like genetics, diet, and environment. The gut microbiome is the most populated and plays a key role in digestion and immunity. While a balanced microbiome promotes health, imbalances can lead to conditions such as obesity, metabolic disorders, and inflammatory diseases (Scheithauer et al., 2020).

Importance of Microbiomes in Health and Disease

Microbiomes contribute to digestion, immune function, and protection against harmful pathogens. A stable microbiome supports overall health, whereas microbial imbalances have been associated with various diseases, including autoimmune and metabolic disorders. Therapies such as probiotics, prebiotics, and microbiota transplantation are being explored to restore microbial balance and improve health outcomes (Baldi et al., 2021).

1. MICROBIOME COMPOSITION AND FUNCTION

Microbiomes are composed of diverse microbial communities that vary across different body sites and play essential roles in human health. Each microbiome type has a unique composition and function, influenced by factors such as genetics, environment, and lifestyle. These microbial ecosystems contribute to digestion, immune regulation, and protection against pathogens while also influencing metabolic and neurological functions. The variability between individuals highlights the need for personalized approaches to microbiome-based therapies. Understanding the mechanisms by which microbiomes interact with the host is essential for developing targeted interventions to maintain health and prevent disease (Alanazi et al., 2024).

1.1 Types of Microbiomes: Gut, Skin, Oral, Respiratory, Urogenital, etc.

The human body hosts diverse microbiomes across different anatomical sites, each with distinct microbial compositions and functions. The gut microbiome is the most complex, playing a vital role in digestion, nutrient absorption, and immune regulation. The skin microbiome provides a protective barrier against pathogens and supports wound healing. The oral microbiome influences oral health and systemic conditions, while the respiratory microbiome helps maintain lung immunity. The urogenital microbiome, particularly in females, contributes to reproductive and urinary health. These microbiomes interact with their environments, shaping overall human health and disease susceptibility (Hou et al., 2022).

1.2 Factors Influencing Microbiome Composition: Genetics, Environment, Lifestyle, etc.

Microbiome composition is influenced by genetic, environmental, and lifestyle factors. Genetics can shape microbial diversity by determining immune responses and mucosal barriers. Environmental exposures, such as pollutants and antibiotic use, can alter microbial balance. Lifestyle choices, including diet, physical activity, and hygiene practices, significantly impact microbiome diversity and stability. Other factors, such as stress, sleep patterns, and geographical location, also contribute to interindividual differences in

microbial communities, affecting overall health and disease risk (Ren et al., 2023).

1.3 Functional Roles of Microbiomes in Human Physiology

Microbiomes contribute to essential physiological functions that support human health. They aid in digestion by breaking down complex carbohydrates and synthesizing vitamins and metabolites. The microbiome also plays a key role in immune system development, training immune cells to differentiate between harmful and beneficial microbes. Additionally, microbiomes influence neurological health through the gut-brain axis, affecting mood and cognitive function. These microbial communities help maintain homeostasis by regulating inflammation, protecting against infections, and supporting metabolic processes (Hou et al., 2022).

1.4 Interindividual Variability and Personalization of Microbiomes

Microbiome composition varies significantly between individuals due to genetic, environmental, and lifestyle differences. This variability influences disease susceptibility, drug metabolism, and immune responses. Personalized medicine approaches are emerging to tailor microbiome-based therapies, such as probiotics and dietary interventions, to individual microbial profiles. Understanding interindividual differences allows for more effective strategies in disease prevention, treatment, and overall health optimization (Kerimi et al., 2020).

1.5 Mechanisms of Action of Microbiomes: Metabolic Functions, Immune System Modulation, etc.

Microbiomes exert their effects through metabolic and immunological mechanisms. They produce short-chain fatty acids (SCFAs) that regulate energy metabolism and maintain gut integrity. Microbes also synthesize essential vitamins and bioactive compounds that influence host physiology. In immune modulation, microbiomes help develop and regulate immune responses, preventing excessive inflammation and autoimmune reactions. These mechanisms highlight the critical role of microbiomes in maintaining health and preventing disease (Zheng et al., 2020).

2. MICROBIOMES AND IMMUNE SYSTEM INTERACTIONS

Microbiomes play a crucial role in shaping and regulating the immune system, influencing responses to pathogens, vaccines, and autoimmune conditions. These microbial communities help train immune cells to distinguish between harmful and beneficial organisms, maintaining immune balance. Disruptions in microbiome composition can lead to immune dysregulation, contributing to conditions such as autoimmune diseases, allergies, and altered vaccine efficacy, therefore, understanding the interactions between microbiomes and the immune system can provide insights into potential therapeutic strategies for immune-related disorders (Campbell et al., 2023).

2.1 Mechanisms of Immune Modulation

Microbiomes modulate immune function through various mechanisms, including the production of metabolites, interaction with immune receptors, and regulation of inflammatory pathways. Beneficial microbes produce short-chain fatty acids and other bioactive compounds that enhance immune tolerance and suppress excessive inflammation. They also interact with immune cells in the gut-associated lymphoid tissue, promoting the development of regulatory T cells and balancing immune responses. These mechanisms help maintain immune homeostasis and protect against infections and inflammatory diseases (Iliev et al., 2025).

2.2 The Role of Microbiomes in Autoimmune Diseases and Allergies

Alterations in microbiome composition, known as dysbiosis, have been linked to the development of autoimmune diseases and allergies. An imbalance in microbial diversity can trigger inappropriate immune activation, leading to conditions such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Similarly, disruptions in early-life microbiome development have been associated with an increased risk of allergies and asthma due to improper immune system training. Restoring microbial balance through probiotics, prebiotics, and dietary interventions is being explored as a potential strategy to manage these conditions (De Luca & Shoenfeld, 2019).

2.3 Microbiome Influence on Vaccination Outcomes

Microbiome composition can influence vaccine efficacy by modulating immune responses to vaccination. A diverse and balanced microbiome enhances antigen presentation, antibody production, and long-term immune memory, improving vaccine effectiveness. Conversely, microbiome imbalances, often caused by antibiotic use or poor diet, may impair immune activation and reduce vaccine-induced protection. Research is ongoing to explore how microbiome-targeted interventions can optimize vaccine responses, particularly in vulnerable populations such as infants and the elderly (Liu et al., 2024).

3. MICROBIOMES IN METABOLIC HEALTH

Microbiomes play a significant role in metabolic processes, influencing nutrient absorption, energy balance, and disease susceptibility. A well-balanced microbiome supports metabolic homeostasis, while dysbiosis can contribute to conditions such as obesity, diabetes, and cardiovascular diseases. Microbial communities regulate host metabolism through complex interactions with dietary components, hormone signaling, and inflammatory pathways. Understanding these relationships provides insights into potential microbiome-targeted therapies for metabolic disorders (Montenegro et al., 2023).

3.1 Influence on Host Physiology, Metabolism, Obesity, and Weight Regulation

The gut microbiome plays a crucial role in regulating metabolism by influencing digestion, energy extraction, and fat storage. Certain microbes enhance the breakdown of dietary fiber into short-chain fatty acids, which contribute to energy balance and appetite regulation. Microbial composition differences have been linked to variations in weight gain, with some gut bacteria promoting fat accumulation and others aiding in maintaining a lean body mass. Disruptions in microbial diversity can lead to metabolic imbalances, increasing the risk of obesity and related disorders (Basak et al., 2022).

3.2 Microbiomes and Diabetes: Mechanisms and Evidence

Gut microbiomes are closely associated with glucose metabolism and insulin sensitivity, playing a key role in diabetes development. Beneficial microbes contribute to the production of metabolites that regulate inflammation and improve insulin signaling, whereas dysbiosis is linked to increased gut permeability and systemic inflammation, leading to insulin resistance. Studies have shown that individuals with type 2 diabetes often have an altered microbiome composition, with reduced levels of beneficial bacteria. Targeted interventions, including probiotics and dietary modifications, are being explored to restore microbial balance and improve glycemic control (Sadagopan et al., 2023).

3.3 The Role of Microbiomes in Cardiovascular Health

Microbiomes influence cardiovascular health by regulating lipid metabolism, inflammation, and the production of bioactive compounds such as trimethylamine-N-oxide (TMAO), which has been linked to an increased risk of heart disease. A balanced microbiome helps maintain healthy cholesterol levels and reduces systemic inflammation, lowering the risk of atherosclerosis and hypertension. Dietary factors play a crucial role in shaping the microbiome, with fiber-rich diets promoting heart-protective microbial populations. Nowadays, microbiome-targeted therapies are being explored to support cardiovascular health and reduce disease risk (Arvelaez Pascucci et al., 2024).

3.4 Dysbiosis and Its Role in Disease Development

Dysbiosis, or microbial imbalance, has been implicated in the onset and progression of various metabolic diseases. Disruptions in microbiome composition can lead to increased gut permeability, chronic inflammation, and altered metabolism, contributing to conditions such as obesity, diabetes, and cardiovascular disease. Factors such as antibiotic use, poor diet, and stress can trigger dysbiosis, highlighting the importance of maintaining microbial balance for overall health. Strategies to prevent and correct dysbiosis include dietary interventions, probiotics, and microbiome-based therapeutics aimed at restoring microbial homeostasis (Patra et al., 2023).

4. MICROBIOMES AND MENTAL HEALTH

The gut microbiome plays a significant role in mental health through its interactions with the central nervous system, known as the gut-brain axis. Microbial communities influence neurotransmitter production, stress responses, and inflammation, all of which affect brain function and emotional well-being. Disruptions in the microbiome have been linked to mood disorders, anxiety, and depression, leading to growing interest in microbiome-based therapies for psychiatric conditions (Clapp et al., 2017).

4.1 Mechanisms of Interaction in the Gut-Brain Axis

The gut-brain axis is a bidirectional communication system connecting the gut microbiome with the central nervous system through neural, immune, and endocrine pathways. Microbes influence brain function by producing neurotransmitters such as serotonin, dopamine, and gamma-aminobutyric acid (GABA), which regulate mood and cognition. They also modulate stress hormone responses and inflammatory signaling, affecting mental health. Disruptions in this interaction can contribute to neurological and psychiatric disorders, emphasizing the role of gut microbiota in brain function (Zheng et al., 2023).

4.2 Influence of Microbiomes on Host Behavior and Mood Disorders

Microbiome composition has been linked to mood disorders, including anxiety and depression. Beneficial microbes help regulate stress responses and promote emotional stability, while an imbalance in microbial diversity can lead to increased inflammation and altered neurotransmitter production. Studies suggest that individuals with mood disorders often exhibit distinct microbiome profiles, with lower levels of beneficial bacteria. Dietary interventions, probiotics, and prebiotics are being explored as potential strategies to support mental health by restoring microbial balance (Kumar et al., 2023).

4.3 Potential for Microbiome-Based Therapies in Psychiatry

Emerging research suggests that microbiome-based therapies could offer new treatment options for psychiatric conditions. Probiotics, prebiotics, and dietary interventions aimed at modifying gut microbiota have shown promise in alleviating symptoms of anxiety, depression, and stress-related disorders. Fecal microbiota transplantation is also being studied for its potential to restore microbial balance and improve mental health outcomes. While still in early stages, microbiome-targeted interventions represent a novel approach to complement traditional psychiatric treatments (Xiong et al., 2023).

5. MICROBIOMES IN INFECTIOUS DISEASES

Microbiomes play a crucial role in protecting against infections by acting as a natural defense system against pathogenic microbes. They help maintain immune balance, compete with harmful bacteria for resources, and produce antimicrobial compounds. However, disruptions in microbiome composition, whether due to disease, antibiotic use, or environmental factors, can increase susceptibility to infections. Understanding these interactions is essential for developing microbiome-based strategies to prevent and manage infectious diseases (Zheng et al., 2024).

5.1 Role of Microbiomes in Pathogen Resistance: Defense Mechanisms

The microbiome acts as a barrier against infections by outcompeting pathogenic microbes for nutrients and adhesion sites, producing antimicrobial peptides, and stimulating immune defenses. Beneficial microbes enhance immune surveillance, preventing the colonization of harmful bacteria, viruses, and fungi. A well-balanced microbiome helps reduce the risk of infections, while dysbiosis can weaken natural defense mechanisms, making individuals more susceptible to diseases (Pickard et al., 2017).

5.2 Impact of Antibiotics on Microbiome Health

While antibiotics are essential for treating bacterial infections, they can also disrupt the microbiome by eliminating beneficial microbes along with harmful pathogens. This disruption can lead to dysbiosis, increasing

susceptibility to opportunistic infections such as Clostridioides difficile and antibiotic-resistant bacteria. Long-term antibiotic use has also been linked to immune dysregulation and metabolic disorders. Strategies such as probiotics and microbiome restoration therapies are being explored to mitigate the negative effects of antibiotics on microbial health (Dahiya & Nigam, 2023).

5.3 Case Studies: Microbiomes in COVID-19 and Other Infectious Diseases

Research has shown that microbiome composition influences susceptibility to and severity of infectious diseases, including COVID-19. Studies indicate that patients with severe COVID-19 often exhibit gut microbiome imbalances, characterized by reduced beneficial bacteria and increased inflammation-associated microbes. Similar patterns have been observed in other infectious diseases, suggesting that microbiome health plays a role in immune resilience. Exploring microbiome-targeted therapies may provide new approaches for managing infectious diseases and improving recovery outcomes (Zhong et al., 2023).

6. THERAPEUTIC APPLICATIONS OF MICROBIOMES

Advancements in microbiome research have led to the development of therapeutic strategies aimed at restoring microbial balance and improving health outcomes. Approaches such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and microbiome engineering offer promising avenues for treating various diseases. These therapies target conditions ranging from gastrointestinal disorders to metabolic and neurological diseases, highlighting the potential of microbiome-based interventions in personalized medicine (Yaqub et al., 2025).

6.1 Probiotics and Prebiotics: Mechanisms and Efficacy

Probiotics are live beneficial bacteria that help restore microbiome balance, while prebiotics are non-digestible fibers that promote the growth of these beneficial microbes. Both have shown efficacy in improving gut health, enhancing immune function, and reducing inflammation. Probiotics have been used to treat conditions such as irritable bowel syndrome, antibiotic-associated

diarrhea, and allergies, while prebiotics support a healthy microbiome by providing essential nutrients for beneficial bacteria. Their therapeutic potential continues to be explored for broader applications in metabolic and neurological disorders (Zhou et al., 2024).

6.2 Fecal Microbiota Transplantation (FMT): Current Practices and Future Directions

FMT involves transferring stool from a healthy donor to a recipient to restore microbiome balance, and is primarily used for treating recurrent Clostridioides difficile infections. The procedure has shown remarkable success in re-establishing gut microbial diversity and reducing infection recurrence. Research is expanding into FMT's potential applications in inflammatory bowel disease, metabolic disorders, and even neurological conditions. Future directions focus on refining donor selection, developing standardized formulations, and exploring synthetic microbiome transplants for safer and more controlled therapeutic use (Yadegar et al., 2023).

6.3 Emerging Therapies: Microbiome Manipulation/Engineering and Personalized Medicine

Innovative microbiome-based therapies are emerging, including microbiome engineering and personalized interventions tailored to an individual's microbial composition. Advances in synthetic biology and gene editing allow for the design of probiotics with specific therapeutic functions, such as producing anti-inflammatory compounds or enhancing immune regulation. Personalized microbiome analysis enables targeted treatments based on an individual's unique microbial profile, improving the precision and efficacy of therapies. These approaches hold great promise for revolutionizing healthcare by leveraging the microbiome to prevent and treat a wide range of diseases (Nazir et al., 2024).

7. CHALLENGES AND FUTURE DIRECTIONS

Despite the growing interest in microbiome research, several challenges remain in translating findings into clinical applications. Ethical concerns, data standardization issues, and the complexity of microbiome interactions pose significant obstacles. However, advances in multi-OMICs technologies and personalized medicine offer promising opportunities for future research and therapeutic development. Addressing these challenges will be crucial for fully harnessing the potential of microbiome science in healthcare (Ejtahed et al., 2023).

7.1 Ethical Considerations in Microbiome Research

Microbiome research raises ethical concerns regarding data privacy, informed consent, and potential misuse of microbiome-based interventions. The collection and analysis of personal microbiome data must adhere to strict ethical guidelines to protect individuals' rights and confidentiality. Additionally, equitable access to microbiome-based therapies remains a challenge, as socioeconomic disparities may limit availability. Ethical frameworks must evolve alongside scientific advancements to ensure responsible microbiome research and application (Ma et al., 2018).

7.2 Challenges in Microbiome Data Interpretation and Standardization

Interpreting microbiome data is complex due to variations in sequencing techniques, sample collection methods, and individual microbiome diversity. The lack of standardized protocols makes it difficult to compare findings across studies, hindering reproducibility and clinical translation. Establishing universal guidelines for microbiome research, including standardized bioinformatics tools and reference databases, is essential for improving data reliability and facilitating the development of evidence-based microbiome therapies (Kumar et al., 2024).

7.3 Future Research Directions and Clinical Applications: Multi-OMICs

The integration of multi-OMICs approaches, including genomics, transcriptomics, proteomics, and metabolomics, provides a comprehensive understanding of microbiome functions and host interactions. These advanced techniques enable more precise identification of microbial biomarkers for disease prediction, diagnosis, and treatment. Future research will focus on leveraging multi-OMICs data to develop personalized microbiome-based therapies, optimizing interventions for conditions such as metabolic disorders, neurological diseases, and immune-related conditions. As technology advances, microbiome science is expected to play a transformative role in precision medicine and healthcare (Chetty & Blekhman, 2024).

SUMMARY, CONCLUSION, AND RECOMMENDATIONS

Microbiome research has significantly advanced our understanding of human health and disease, revealing its crucial role in immunity, metabolism, mental health, and infectious disease resistance. While therapeutic applications such as probiotics, FMT, and microbiome engineering show promise, challenges remain in data interpretation, ethical considerations, and standardization. Addressing these challenges will be essential for fully integrating microbiome-based interventions into clinical practice.

Summary of Key Findings

The key ideas highlighted in this chapter point towards the fact that the human microbiome plays a fundamental role in maintaining health, influencing immune responses, metabolic processes, neurological function, and disease susceptibility. On the other hand, disruptions in microbiome composition, known as dysbiosis, have been linked to various conditions, including obesity, diabetes, cardiovascular diseases, autoimmune disorders, and mental health issues. Advances in microbiome-based therapies, such as probiotics, prebiotics, and microbiome transplantation, highlight the potential of harnessing microbial communities for disease prevention and treatment.

The Future of Microbiome Research in Health and Disease

We hypothesize that future microbiome research will focus on personalized medicine, integrating multi-OMICs approaches to develop targeted microbiome-based therapies. Technological advancements in sequencing, synthetic biology, and artificial intelligence will enhance our ability to manipulate microbiomes for therapeutic purposes. Ethical frameworks and standardized protocols must evolve alongside scientific progress to ensure responsible application. As microbiome science continues to advance, its integration into mainstream healthcare has the potential to revolutionize disease prevention, diagnosis, and treatment.

REFERENCES

Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2022). Microbiome and human health: Current understanding, engineering, and enabling technologies. Chemical Reviews, 123(1), 31–72. https://doi.org/10.1021/acs.chemrev.2c00431

Alanazi, A., Younas, S., Ejaz, H., Mazhari, B. B. Z., Abosalif, K., Abdalla, A. E., Alruwaili, M., Atif, M., & Junaid, K. (2024). Exploration of the human microbiome's role in health and disease through the lens of genetics. Journal of Pure and Applied Microbiology, 18(3), 1413–1423. https://doi.org/10.22207/jpam.18.3.61

Arvelaez Pascucci, J., Ghattas, P. E., Olivas Lerma, R., Villa Nogueyra, S., Nogales Bernal, M. B., Milani, V., Floridia Rietmann, L. M., Alvarez, S. M., & Salaz Diaz, J. (2024). The role of microbiome in cardiovascular health: Insights for primary care interventions. Cureus, 16(9), e70311. https://doi.org/10.7759/cureus.70311

Baldi, S., Mundula, T., Nannini, G., & Amedei, A. (2021). Microbiota shaping — the effects of probiotics, prebiotics, and fecal microbiota transplant on cognitive functions: A systematic review. World Journal of Gastroenterology, 27, 6715 - 6732. https://doi.org/10.3748/wjg.v27.i39.6715

Basak, S., Banerjee, A., Pathak, S., & Duttaroy, A. K. (2022). Dietary fats and the gut microbiota: Their impacts on lipid-induced metabolic syndrome. Journal of Functional Foods, 91, 105026. https://doi.org/10.1016/j.jff.2022.105026

Campbell, C., Kandalgaonkar, M. R., Golonka, R. M., Yeoh, B. S., Vijay-Kumar, M., & Saha, P. (2023). Crosstalk between gut microbiota and host immunity: Impact on inflammation and immunotherapy. Biomedicines, 11(2), 294. https://doi.org/10.3390/biomedicines11020294

Chetty, A., & Blekhman, R. (2024). Multi-omic approaches for host-microbiome data integration. Gut Microbes, 16(1), 2297860. https://doi.org/10.1080/19490976.2023.2297860

Cho, I., & Blaser, M. J. (2012). The human microbiome: At the interface of health and disease. Nature Reviews Genetics, 13(4), 260–270. https://doi.org/10.1038/nrg3182

Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., & Wakefield, S. (2017). Gut microbiota's effect on mental health: The gut-brain axis. Clinics and Practice, 7(4), 987. https://doi.org/10.4081/cp.2017.987

Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012). The impact of the gut microbiota on human health: An integrative view. Nature, 488(7410), 178–184. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418802/

Dahiya, D., & Nigam, P. S. (2023). Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. International Journal of Molecular Sciences, 24(4), 3074. https://doi.org/10.3390/ijms24043074

De Luca, F., & Shoenfeld, Y. (2019). The microbiome in autoimmune diseases. Clinical and Experimental Immunology, 195(1), 74–85. https://doi.org/10.1111/cei.13158

Ejtahed, H. S., Parsa, M., & Larijani, B. (2023). Ethical challenges in conducting and the clinical application of human microbiome research. Journal of Medical Ethics and History of Medicine, 16, 5. https://doi.org/10.18502/jmehm.v16i5.13313

Gilbert, J. A., Quinn, R. A., Debelius, J., Xu, Z. Z., Morton, J., Garg, N., Jansson, J. K., Dorrestein, P. C., & Knight, R. (2016). Microbiome-wide association studies link dynamic microbial consortia to disease. Nature, 535(7610), 94–103. https://doi.org/10.1038/nature18850

Hou, K., Wu, Z., Chen, X., Wang, J., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J., & Chen, Z. (2022). Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 7(1). https://doi.org/10.1038/s41392-022-00974-4

Iliev, I. D., Ananthakrishnan, A. N. & Guo, C. J. (2025). Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nature Reviews Microbiology, 2025. https://doi.org/10.1038/s41579-025-01163-0

Kerimi, A., Kraut, N. U., Da Encarnacao, J. A., & Williamson, G. (2020). The gut microbiome drives inter- and intra-individual differences in metabolism of bioactive small molecules. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-76558-5

Kumar, A., Pramanik, J., Goyal, N., Chauhan, D., Sivamaruthi, B. S., Prajapati, B. G., & Chaiyasut, C. (2023). Gut microbiota in anxiety and depression: Unveiling the relationships and management options. Pharmaceuticals, 16(4), 565. https://doi.org/10.3390/ph16040565

Kumar, B., Lorusso, E., Fosso, B., & Pesole, G. (2024). A comprehensive overview of microbiome data in the light of machine learning applications: categorization, accessibility, and future directions. Frontiers in Microbiology, 15, 1343572. https://doi.org/10.3389/fmicb.2024.1343572

Liu, Y., Zhou, J., Yang, Y., Chen, X., Chen, L., & Wu, Y. (2024). Intestinal microbiota and its effect on vaccine-induced immune amplification and tolerance. Vaccines, 12(8), 868. https://doi.org/10.3390/vaccines12080868

Lloyd-Price, J., Abu-Ali, G., & Huttenhower, C. (2016). The healthy human microbiome. Genome Medicine, 8(1). https://doi.org/10.1186/s13073-016-0307-y

Ma, Y., Chen, H., Lan, C., & Ren, J. (2018). Help, hope and hype: ethical considerations of human microbiome research and applications. Protein & Cell, 9(5), 404–415. https://doi.org/10.1007/s13238-018-0537-4

Maier, L., Pruteanu, M., Kuhn, M., Zeller, G., Telzerow, A., Anderson, E. E., Brochado, A. R., Fernandez, K. C., Dose, H., Mori, H., Patil, K. R., Bork, P., & Typas, A. (2023). Extensive impact of non-antibiotic drugs on human gut bacteria. Nature, 555(7698), 623–628. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837825/

Marchesi, J. R., & Ravel, J. (2015). The vocabulary of microbiome research: A proposal. Microbiome, 3, 31. https://doi.org/10.1186/s40168-015-0094-5

Montenegro, J., Armet, A. M., Willing, B. P., Deehan, E. C., Fassini, P. G., Mota, J. F., Walter, J., & Prado, C. M. (2023). Exploring the influence of gut microbiome on energy metabolism in humans. Advances in Nutrition, 14(4), 840–857. https://doi.org/10.1016/j.advnut.2023.03.015

Nazir, A., Hussain, F. H. N., & Raza, A. (2024). Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine. Frontiers in Bioengineering and

Biotechnology, 12, 1511149. https://doi.org/10.3389/fbioe.2024.1511149

Ogunrinola, G. A., Oyewale, J. O., Oshamika, O. O., & Olasehinde, G. I. (2020). The human microbiome and its impacts on health. International Journal of Microbiology, 2020, 8045646, 1–7. https://doi.org/10.1155/2020/8045646

Patra, D., Banerjee, D., Ramprasad, P., Roy, S., Pal, D., & Dasgupta, S. (2023). Recent insights of obesity-induced gut and adipose tissue dysbiosis in type 2 diabetes. Frontiers in Molecular Biosciences, 10, 1224982. https://doi.org/10.3389/fmolb.2023.1224982

Pickard, J. M., Zeng, M. Y., Caruso, R., & Núñez, G. (2017). Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunological Reviews, 279(1), 70–89. https://doi.org/10.1111/imr.12567

Proctor, L. M. (2016). The National Institutes of Health Human Microbiome Project. Seminars in Fetal and Neonatal Medicine, 21(6), 368–372. https://doi.org/10.1016/j.siny.2016.05.002

Ren, Y., Wu, J., Wang, Y., Zhang, L., Ren, J., Zhang, Z., Chen, B., Zhang, K., Zhu, B., Liu, W., Li, S., & Li, X. (2023). Lifestyle patterns influence the composition of the gut microbiome in a healthy Chinese population. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-41532-4

Sadagopan, A., Mahmoud, A., Begg, M., Tarhuni, M., Fotso, M., Gonzalez, N. A., Sanivarapu, R. R., Osman, U., Latha Kumar, A., & Mohammed, L. (2023). Understanding the role of the gut microbiome in diabetes and therapeutics targeting leaky gut: A systematic review. Cureus, 15(7), e41559. https://doi.org/10.7759/cureus.41559

Scheithauer, T., Scheithauer, T., Rampanelli, E., Nieuwdorp, M., Nieuwdorp, M., Vallance, B., Verchere, C., Raalte, D., Raalte, D., & Herrema, H. (2020). Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Frontiers in Immunology, 11, 571731. https://doi.org/10.3389/fimmu.2020.571731

Shreiner, A. B., Kao, J. Y., & Young, V. B. (2015). The gut microbiome in health and in disease. Current Opinion in Gastroenterology, 31(1), 69–75. https://doi.org/10.1097/MOG.0000000000000139

Yadegar, A., Pakpoor, S., Ibrahim, F. F., Nabavi-Rad, A., Cook, L., Walter, J., Seekatz, A. M., Wong, K., Monaghan, T. M., & Kao, D. (2023). Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection. Cell Host & Microbe, 31(5), 695–711. https://doi.org/10.1016/j.chom.2023.03.019

Yaqub, M. O., Jain, A., Joseph, C. E., & Edison, L. K. (2025). Microbiome-driven therapeutics: From gut health to precision medicine. Gastrointestinal Disorders, 7(1), 7. https://doi.org/10.3390/gidisord7010007

Zheng, D., Liwinski, T., & Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. Cell Research, 30(6), 492–506. https://doi.org/10.1038/s41422-020-0332-7

Zheng, Y., Bonfili, L., Wei, T., & Eleuteri, A. M. (2023). Understanding the Gut-Brain Axis and its therapeutic implications for neurodegenerative disorders. Nutrients, 15(21), 4631. https://doi.org/10.3390/nu15214631

Zhong, M. M., Xie, J. H., Feng, Y., Zhang, S. H., Xia, J. N., Tan, L., Chen, N. X., Su, X. L., Zhang, Q., Feng, Y. Z., & Guo, Y. (2023). Causal effects of the gut microbiome on COVID-19 susceptibility and severity: A two-sample Mendelian randomization study. Frontiers in Immunology, 14, 1173974. https://doi.org/10.3389/fimmu.2023.1173974

Zhou, P., Chen, C., Patil, S., & Dong, S. (2024). Unveiling the therapeutic symphony of probiotics, prebiotics, and postbiotics in gut-immune harmony. Frontiers in Nutrition, 11, 1355542. https://doi.org/10.3389/fnut.2024.1355542

Zmora, N., Suez, J., & Elinav, E. (2018). You are what you eat: Diet, health and the gut microbiota. Nature Reviews Gastroenterology & Hepatology, 15(1), 35–56. https://doi.org/10.1038/nrgastro.2017.217

CHAPTER 6
MICROBIOTA AND ITS IMPACT ON DISEASE PATHOGENESIS: INSIGHTS INTO GUT HEALTH AND BEYOND

S. KALAISELVAN[1]
M. Devi SRI[2]
K. Mohana PRIYA[3]
V. JEEVANANTHAN[4]

[1]Rathinam Technical Campus, Department of Chemistry, Coimbatore, Tamilnadu, India, kalaichem82@gmail.com
[2]Department of Biotechnology, Rathinam Technical Campus, Coimbatore, Tamilnadu, India
[3]Department of Biotechnology, Rathinam Technical Campus, Coimbatore, Tamilnadu, India
[4] Rathinam Technical Campus, Department of Chemistry, Coimbatore, Tamilnadu, India

INTRODUCTION

The human body is home to trillions of microorganisms, collectively known as the microbiota. These microbial populations exist in symbiosis with the host, playing a crucial role in maintaining homeostasis and regulating various physiological processes. The microbiota is composed of diverse communities of bacteria, viruses, fungi, and protozoa that reside in different parts of the body, including the skin, respiratory tract, gastrointestinal tract, and genitourinary tract. The gut microbiota, in particular, is the most densely populated and diverse ecosystem, with estimates suggesting that it contains over 100 trillion microorganisms.

The microbiota plays a vital role in maintaining human health, and its dysregulation has been implicated in various disease processes. The microbiota influences various physiological processes, including digestion, metabolism, and immune system function, and brain function. It produces essential nutrients, such as vitamins and hormones, and regulates the expression of genes involved in inflammation and immune responses. The microbiota also maintains the integrity of the epithelial barrier, preventing the translocation of pathogens and toxins into the bloodstream. Furthermore, it regulates the immune system, inducing the production of antimicrobial peptides and regulating the activity of immune cells, such as macrophages and T cells.

The microbiota is also involved in the regulation of various metabolic processes, including glucose metabolism, lipid metabolism, and energy homeostasis. It produces short-chain fatty acids (SCFAs), which serve as energy sources for colonocytes and regulate the expression of genes involved in inflammation and immune responses. The microbiota also influences the gut-brain axis, producing metabolites that modulate mood, cognitive function, and behavior.

An imbalance of the microbiota, also known as dysbiosis, has been linked to various disease processes, including inflammatory bowel disease, obesity, metabolic disorders, and mental health disorders. Dysbiosis can lead to impaired immune function, increased inflammation, and altered metabolic processes, ultimately contributing to the development and progression of disease. Understanding the complex interactions between the microbiota and

the host is essential for elucidating the mechanisms underlying these diseases and developing effective therapeutic strategies.

Recent advances in high-throughput sequencing technologies and bioinformatics tools have enabled the characterization of the microbiota in unprecedented detail, providing new insights into its role in human health and disease. The study of the microbiota has also led to the development of new therapeutic strategies, including probiotics, prebiotics, and fecal microbiota transplantation. These therapies aim to restore the balance of the microbiota and promote the growth of beneficial microorganisms, ultimately leading to improved human health.

1. MICROBIOTA IN NORMAL CONDITIONS

In normal conditions, the human microbiota plays a crucial role in maintaining homeostasis and regulating various physiological processes. The gut microbiota, in particular, is a complex ecosystem composed of trillions of microorganisms that live in symbiosis with the host. These microorganisms, including bacteria, viruses, fungi, and protozoa, work together to maintain a delicate balance that is essential for human health.

One of the primary functions of the gut microbiota is to digest and process nutrients from the food we eat. The microbiota produces enzymes that break down complex carbohydrates, proteins, and fats, making it possible for the body to absorb the nutrients it needs. The gut microbiota also produces certain vitamins, such as vitamin K and biotin that are essential for human health.

In addition to its role in digestion and nutrition, the gut microbiota also plays a crucial role in maintaining immune system function. The microbiota produces antimicrobial peptides and regulates the activity of immune cells, such as macrophages and T cells, to prevent infection and disease. The gut microbiota also produces metabolites that regulate the expression of genes involved in inflammation and immune responses, helping to maintain a healthy balance between pro-inflammatory and anti-inflammatory responses.

The gut microbiota also influences the gut-brain axis, producing metabolites that modulate mood, cognitive function, and behaviour. The production of neurotransmitters, such as serotonin and dopamine, is regulated

by the gut microbiota, and alterations in the gut microbiota have been linked to various mental health disorders, including anxiety and depression.

Furthermore, the gut microbiota maintains the integrity of the epithelial barrier, preventing the translocation of pathogens and toxins into the bloodstream. The gut microbiota also regulates the expression of genes involved in inflammation and immune responses, helping to maintain a healthy balance between pro-inflammatory and anti-inflammatory responses.

2. PATHOGENESIS OF DYSBIOSIS

The pathogenesis of dysbiosis is a complex and multifaceted process, involving the disruption of the delicate balance between the microbiota and the host. Dysbiosis can occur due to various factors, including antibiotics, diet, stress, and environmental toxins, which can alter the composition and function of the microbiota. One of the primary mechanisms underlying dysbiosis is the disruption of the gut epithelial barrier, allowing the translocation of pathogens and toxins into the bloodstream.

This can trigger a systemic inflammatory response, characterized by the activation of immune cells, the release of pro-inflammatory cytokines, and the production of reactive oxygen species. The inflammatory response can further exacerbate dysbiosis, creating a vicious cycle of inflammation and microbial imbalance. Additionally, dysbiosis can lead to the overgrowth of opportunistic pathogens, such as Clostridioides difficile, which can produce toxins that further disrupt the microbiota and exacerbate disease.

Furthermore, dysbiosis can also impair the function of immune cells, such as macrophages and T cells, making it difficult for the host to clear infections and maintain immune homeostasis. The metabolic activity of the microbiota is also disrupted in dysbiosis, leading to changes in the production of short-chain fatty acids, vitamins, and hormones, which can have far-reaching consequences for host metabolism and physiology.

The gut-brain axis is also disrupted in dysbiosis, leading to changes in mood, cognitive function, and behavior. The production of neurotransmitters, such as serotonin and dopamine, is altered, leading to changes in mood and cognitive function. Additionally, the disruption of the gut-brain axis can also lead to changes in behavior, such as increased anxiety and stress.

Overall, the pathogenesis of dysbiosis is a complex process, involving the disruption of the delicate balance between the microbiota and the host. Understanding the mechanisms underlying dysbiosis is essential for developing effective therapeutic strategies to restore the balance of the microbiota and promote human health.

3. GUT MICROBIOTA

The gut microbiota is a complex ecosystem composed of trillions of microorganisms that live in the gastrointestinal tract. These microorganisms, including bacteria, viruses, fungi, and protozoa, play a crucial role in maintaining gut health and regulating various physiological processes. The gut microbiota is responsible for digesting complex nutrients, synthesizing essential vitamins, and regulating energy metabolism. It also produces short-chain fatty acids (SCFAs), which serve as energy sources for colonocytes and regulate the expression of genes involved in inflammation and immune responses. Moreover, the gut microbiota influences the gut-brain axis, producing metabolites that modulate mood, cognitive function, and behavior. The gut microbiota also maintains the integrity of the epithelial barrier, preventing the translocation of pathogens and toxins into the bloodstream. Furthermore, it regulates the immune system, inducing the production of antimicrobial peptides and regulating the activity of immune cells, such as macrophages and T cells.

The gut microbiota is also involved in the regulation of the gut-associated lymphoid tissue (GALT), which is responsible for the production of antibodies and the activation of immune cells. An imbalance of the gut microbiota, also known as dysbiosis, has been implicated in various disease processes, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), obesity, and metabolic disorders. Dysbiosis can lead to impaired immune function, increased inflammation, and altered metabolic processes, ultimately contributing to the development and progression of disease.



Fig 1: Schematic diagram visually represents how the gut microbiota is linked to various health issue

4. LUNG MICROBIOTA

The human respiratory system, once considered a sterile environment, is now recognized to harbor a diverse community of microorganisms known as the lung microbiota. This complex ecosystem consists of bacteria, viruses, fungi, and other microbes that play a significant role in maintaining respiratory health. The lung microbiota is influenced by various factors, including inhaled air, micro aspiration from the oral cavity, host immunity, and environmental conditions. Unlike the gut microbiota, which remains relatively stable, the lung microbiota is more dynamic due to continuous exposure to external microbes and host immune responses. The balance of these microbial communities is essential for maintaining lung homeostasis, protecting against infections, and modulating immune function.

The composition of lung microbiota varies between healthy individuals and those with respiratory diseases. In a healthy state, the predominant bacterial genera include Streptococcus, Veillonella, Prevotella, and Neisseria, which originate from the upper respiratory tract. These bacteria contribute to immune tolerance and prevent the overgrowth of pathogenic microbes. However, in individuals with respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, there is an alteration in microbial

diversity. Conditions such as dysbiosis, characterized by an imbalance in microbial composition, may lead to inflammation, increased susceptibility to infections, and worsening of lung diseases. Pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiellapneumoniae often dominate in disease conditions, exacerbating respiratory symptoms and lung damage.

The lung microbiota interacts closely with the host immune system, influencing both innate and adaptive immune responses. Commensal bacteria in the lungs contribute to immune homeostasis by regulating inflammatory pathways and enhancing mucosal defense mechanisms. For instance, beneficial microbes produce metabolites that modulate the production of cytokines and antimicrobial peptides, thereby preventing excessive inflammation. Conversely, an imbalance in microbial communities can trigger immune dysregulation, leading to chronic inflammation and tissue damage. The interplay between the lung microbiota and immune system also has systemic effects, as lung-derived microbial products can influence immune responses in distant organs.

Several factors impact the composition and function of the lung microbiota. These include genetics, age, diet, smoking, air pollution, antibiotic use, and underlying health conditions. For example, smoking disrupts microbial diversity, promoting the growth of harmful bacteria linked to lung diseases. Similarly, long-term antibiotic use can deplete beneficial microbes, leading to an increased risk of respiratory infections. Environmental pollutants and dietary habits also influence microbial composition, further emphasizing the need for lifestyle modifications to support lung health. Understanding these factors can help develop targeted therapies to restore microbial balance in respiratory diseases.

Emerging research on lung microbiota highlights its potential role in precision medicine and therapeutic interventions. Probiotics, prebiotics, and microbiome-based treatments are being explored to restore microbial equilibrium in lung diseases. Additionally, microbiota profiling through advanced sequencing technologies provides valuable insights into disease pathogenesis, enabling early diagnosis and personalized treatment strategies. Despite these advancements, further research is needed to fully understand the intricate mechanisms governing lung microbiota and its implications for

respiratory health. As scientific knowledge continues to expand, harnessing the power of lung microbiota may pave the way for innovative therapies in respiratory medicine.

5. ORAL CAVITY MICROBIOTA

The oral cavity is home to one of the most diverse and dynamic microbial communities in the human body. The oral microbiota consists of bacteria, fungi, viruses, and archaea that coexist in a delicate balance, contributing to oral and systemic health. With more than 700 bacterial species identified, the oral microbiome plays a critical role in maintaining oral homeostasis, aiding digestion, and preventing the colonization of harmful pathogens. The primary habitats for these microorganisms include the tongue, teeth, gums, saliva, and mucosal surfaces, each providing a unique environment for microbial colonization. Factors such as diet, oral hygiene, genetics, and lifestyle significantly influence the composition and stability of oral microbiota.

In a healthy oral environment, the predominant bacterial genera include Streptococcus, Actinomyces, Veillonella, Fusobacterium, and Prevotella. These bacteria contribute to essential physiological functions, such as breaking down food, producing antimicrobial peptides, and modulating immune responses. Saliva plays a crucial role in maintaining microbial equilibrium by washing away excess bacteria and providing enzymes that regulate microbial activity. However, when the balance of the oral microbiota is disrupted, a condition known as dysbiosis occurs, leading to oral diseases such as dental caries, periodontitis, and oral candidiasis. This imbalance often results from factors like poor oral hygiene, high sugar consumption, smoking, and antibiotic use.

Dental plaque, a biofilm formed by microbial communities on tooth surfaces, is a prime example of how oral microbiota can shift from a commensal state to a pathogenic one. When plaque accumulates due to inadequate oral hygiene, it fosters the growth of harmful bacteria such as Streptococcus mutans and Porphyromonasgingivalis, which are associated with tooth decay and gum disease. S. mutans metabolizes sugars into acids that erode tooth enamel, leading to cavities, while P. gingivalis contributes to the inflammatory destruction of gum tissues, resulting in periodontitis. Chronic periodontitis has also been linked to systemic diseases such as cardiovascular disease, diabetes,

and respiratory infections, highlighting the critical role of oral microbiota beyond the mouth.

The interaction between oral microbiota and the immune system is vital for maintaining a healthy balance. Commensal bacteria help train the immune system by stimulating the production of antibodies and regulating inflammatory responses. However, when pathogenic microbes dominate, they can evade immune defenses and trigger chronic inflammation. The oral microbiota also influences gut microbiota, as bacteria from the mouth are constantly swallowed and contribute to the microbial composition of the digestive tract. Research suggests that oral dysbiosis may contribute to gut-related diseases, including inflammatory bowel disease and colorectal cancer, further emphasizing the systemic impact of oral health.

Advancements in microbiome research are paving the way for novel approaches to maintaining oral health. Probiotics, prebiotics, and microbiome-targeted therapies are being explored to restore microbial balance and prevent oral diseases. Improved diagnostic tools, such as microbial sequencing, enable early detection of dysbiosis-related conditions, allowing for personalized treatment strategies. While oral microbiota research continues to evolve, it is evident that maintaining a healthy microbial balance in the mouth is crucial for overall well-being. Regular oral hygiene, a balanced diet, and lifestyle modifications can help support a stable oral microbiome and prevent disease development.

6. SIGNIFICANCE OF MICROBIOTA

The human microbiota plays a vital role in maintaining human health and preventing disease. The significance of microbiota can be understood from its various functions, including digestion, metabolism, immune system modulation, and production of essential nutrients. The gut microbiota, in particular, is responsible for digesting complex nutrients, synthesizing essential vitamins, and regulating energy metabolism. It also produces short-chain fatty acids (SCFAs), which serve as energy sources for colonocytes and regulate the expression of genes involved in inflammation and immune responses.

The microbiota also plays a crucial role in immune system modulation, regulating the activity of immune cells, such as macrophages and T cells, and

producing antimicrobial peptides to prevent infection. The gut-brain axis, mediated by the microbiota, influences mood, cognitive function, and behavior, highlighting the complex interactions between the microbiota and the host. The microbiota also maintains the integrity of the epithelial barrier, preventing the translocation of pathogens and toxins into the bloodstream.

Furthermore, the microbiota produces metabolites that regulate gene expression, modulate the immune system, and maintain the integrity of the epithelial barrier. The microbiota also influences the development and function of various organs, including the gut, liver, and pancreas. An imbalance of the microbiota, also known as dysbiosis, has been linked to various disease processes, including inflammatory bowel disease, obesity, metabolic disorders, and mental health disorders.

Understanding the significance of microbiota is essential for developing effective therapeutic strategies to promote human health and prevent disease. The study of microbiota has led to the development of new therapies, including probiotics, prebiotics, and fecal microbiota transplantation. These therapies aim to restore the balance of the microbiota and promote the growth of beneficial microorganisms, ultimately leading to improved human health.

In conclusion, the significance of microbiota cannot be overstated. The microbiota plays a vital role in maintaining human health, regulating various physiological processes, and preventing disease. Understanding the complex interactions between the microbiota and the host is essential for developing effective therapeutic strategies to promote human health and prevent disease.

7. ENVIRONMENTAL FACTORS AND INFLUENCES

Environmental factors and influences play a significant role in shaping the composition and function of the human microbiota. One of the most critical environmental factors is diet, which can either promote or disrupt the balance of the microbiota. A diet rich in fruits, vegetables, and whole grains provides essential nutrients and fiber that promote the growth of beneficial microorganisms. On the other hand, a diet high in processed foods, sugar, and unhealthy fats can lead to an imbalance of the microbiota, favoring the growth of pathogenic microorganisms.

Another significant environmental factor is exposure to antibiotics, which can disrupt the balance of the microbiota by killing off beneficial microorganisms. This can lead to an overgrowth of opportunistic pathogens, such as Clostridioides difficile, which can cause severe diarrhea and colitis. Additionally, exposure to environmental toxins, such as pesticides and heavy metals, can also disrupt the balance of the microbiota, leading to changes in the composition and function of the microbiota.

Stress is another environmental factor that can influence the microbiota. Chronic stress can lead to changes in the composition and function of the microbiota, favoring the growth of pathogenic microorganisms. This can lead to a range of symptoms, including digestive problems, anxiety, and depression. Furthermore, lack of sleep and disrupted circadian rhythms can also impact the microbiota, leading to changes in the composition and function of the microbiota.

Geographic location and climate can also influence the microbiota. For example, individuals living in urban areas tend to have a less diverse microbiota compared to those living in rural areas. Additionally, exposure to sunlight and vitamin D can also impact the microbiota, with vitamin D playing a role in regulating the immune system and maintaining the integrity of the epithelial barrier.

Finally, mode of delivery at birth and breastfeeding can also influence the development of the microbiota in infants. Infants born via cesarean section tend to have a less diverse microbiota compared to those born vaginally. Additionally, breastfeeding provides essential nutrients and immune factors that promote the growth of beneficial microorganisms in the infant microbiota. Overall, environmental factors and influences play a critical role in shaping the composition and function of the human microbiota, and understanding these factors is essential for promoting a healthy balance of the microbiota.

CONCLUSION

In conclusion, the microbiota plays a crucial role in maintaining health and preventing disease. Dysbiosis of the microbiota can lead to deregulation of body function and disease processes. Further research is needed to elucidate the mechanisms underlying the relationship between the microbiota and disease, as well as to develop effective clinical approaches for modulating the microbiota for disease treatment.

REFERENCES

Belkaid et al. (2014). Compartmentalized control of skin immunity by resident commensals. Science, 343(6175), 1243-1246.

Bravo et al. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences, 108(38), 16050-16055.

Cammarota et al. (2019). Fecal microbiota transplantation for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis. Clinical Infectious Diseases, 68(11), 1835-1843.

Clemente et al. (2012). The gut microbiota and host health. Nature, 489(7415), 122-126.

Cryan et al. (2012). The gut-brain axis. Nature Reviews Neuroscience, 13(10), 701-712.

Foster et al. (2017). The gut-brain axis in psychiatric disorders. Nature Reviews Neuroscience, 18(10), 661-67

Honda et al. (2011). Intestinal immunoglobulin A and its role in maintaining mucosal homeostasis. Nature Reviews Immunology, 11(2), 131-141.

Hooper et al. (2012). Interactions between the microbiota and the immune system. Science, 336(6086), 1268-1273.

Huang et al. (2013). The role of the gut microbiota in respiratory disease. European Respiratory Journal, 42(4), 857-866.

Koeth et al. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine, 19(5), 576-585.

Mazmanian et al. (2005). An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell, 122(1), 107-118.

Round et al. (2010). The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology, 10(5), 313-323.

Sanders et al. (2019). An update on the use and interpretation of the human microbiome in health and disease. Nature Medicine, 25(3), 329-337.

Schwabe et al. (2013). The gut microbiota and cancer. Nature Reviews Cancer, 13(10), 690-701.

Sonnenburg et al. (2014). Diet-microbiota interactions as modulators of human health. Nature, 513(7518), 242-249.

Tang et al. (2013). Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development and progression of non-alcoholic fatty liver disease (NAFLD). Hepatology, 58(4), 1271-1283.

Van Nood et al. (2013). Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine, 368(5), 407-415.

Wang et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature, 472(7341), 57-63.

CHAPTER 7
THE RELATIONSHIP BETWEEN ATTENTION DEFICIT AND GUT MICROBIOTA: A REVIEW FROM A FUNCTIONAL MEDICINE PERSPECTIVE

Hatun Şevval SAĞIN [1]

[1]Istanbul Esenyurt University, Faculty of Health Sciences, Department of Nutrition and Dietetics, Istanbul, Turkey, sevvalsagin@icloud.com, 0009-0001-3620-1299

INTRODUCTION

Attention deficit is a neurodevelopmental disorder characterized by difficulty in sustaining attention, heightened sensitivity to external stimuli, impaired task completion, and reduced organizational abilities. Although often classified under the broader category of Attention Deficit Hyperactivity Disorder (ADHD), some individuals exhibit predominantly inattentive symptoms without hyperactivity, referred to as the "inattentive subtype" (APA, 2013; Dziegielewski, 2014). Attention deficit is a heterogeneous clinical condition that negatively impacts quality of life, academic achievement, social interactions, and overall functionality. Traditionally explained by dopamine and norepinephrine deficiencies, recent multidisciplinary research suggests that attention deficit cannot be attributed to a single biological cause (Sungur, 2023).

In today's rapidly changing world, attention deficit is increasingly recognized as a growing neurodevelopmental challenge, exacerbated by factors such as digitalization, prolonged screen exposure, environmental toxin load, and chronic stress (Özden, 2021; Güven, 2023). This condition has significant implications not only at the individual level but also on a societal scale (Dalmiş & Yıldırım, 2025). For example, children diagnosed with attention deficit often struggle to adapt to formal education systems, placing an additional burden on teachers and parents and indirectly affecting the quality of education (Sungur, 2023). Among adults, attention deficit has been linked to work-related accidents, decreased productivity, and absenteeism, which collectively result in economic burden and increased demand on healthcare systems (Güven, 2023).

Particularly when beginning in childhood and left untreated, attention deficit may persist into adolescence and adulthood, adversely affecting academic performance, interpersonal relationships, occupational life, and daily functioning (APA, 2013; Dziegielewski, 2014). In recent years, attention deficit has been increasingly conceptualized not solely as a neurologically or genetically based condition, but rather as a multidimensional disorder involving interactions among physiological systems such as the immune response, hormonal regulation, sleep-wake cycles, and gut microbiota (Sungur, 2023; Dalmiş & Yıldırım, 2025).

The emerging concept of the "gut-brain axis" offers a novel framework for understanding the biological and environmental mechanisms underlying

neuropsychiatric disorders, including attention deficit (Wallace & Milev, 2017). Gut microbiota represents a complex ecosystem that influences numerous processes, including neural development, behavioral regulation, and neurotransmitter production (Sungur, 2023). Dysbiosis, or microbial imbalance, has been associated with neuroinflammation and impairments in dopamine metabolism—both commonly observed in individuals with attention deficit (Cenit, Sanz, & Codoñer-Franch, 2017).

This review aims to examine the multifaceted relationship between attention deficit and gut microbiota within the context of current scientific literature and a functional medicine perspective. The study is informed not only by a nutritional viewpoint but also by the author's experience as a primary school teacher, incorporating real-life educational observations. By addressing both clinical and educational dimensions of attention deficit, this work seeks to promote a multidisciplinary approach to understanding and managing the disorder.

1. TYPES OF ATTENTION DEFICIT AND NEUROBIOLOGICAL FOUNDATIONS

Attention deficit is a chronic neurodevelopmental disorder characterized by an individual's inability to sustain attention on specific tasks, heightened sensitivity to external stimuli, mental distractibility, and difficulties in maintaining focus (APA, 2013; Dziegielewski, 2014). This condition adversely affects not only academic performance but also daily life skills, social relationships, and overall functionality. Impairments in executive functions such as planning, time management, task organization, attention to detail, and the ability to complete long-term tasks are among the core outcomes of attention deficit (Sungur, 2023).

Although this disorder is frequently examined under the umbrella of Attention Deficit Hyperactivity Disorder (ADHD), some individuals exhibit only inattentive symptoms without hyperactivity. This subtype is defined as the "predominantly inattentive type" and is often overlooked, particularly in females, adults, and academic settings (Thapar & Cooper, 2016; Özden, 2021). In this respect, attention deficit represents a clinically heterogeneous group that requires individualized intervention strategies.

According to the DSM-5 diagnostic manual, ADHD is classified into three subtypes:

1. **Predominantly Inattentive Type:** The individual has difficulty sustaining attention, frequently overlooks details, fails to follow instructions, and struggles to complete tasks.
2. **Predominantly Hyperactive-Impulsive Type:** Characterized by excessive activity, talkativeness, impatience, and difficulty waiting one's turn.
3. **Combined Type:** Features both inattentiveness and hyperactivity-impulsivity symptoms (APA, 2013; Dziegielewski, 2014).

Global data indicate that ADHD affects approximately 5–7% of children, with prevalence rates decreasing to 4–5% in adolescence and 2.5–4% in adulthood (Polanczyk et al., 2015). A notable increase in reported prevalence has been observed in recent years. Contributing factors include the broadening of diagnostic criteria, increased public awareness, higher clinical referral rates, and intensifying environmental influences (Dalmiş & Yıldırım, 2025; Güven, 2023). Among these environmental risk factors, increased screen exposure, excessive consumption of processed foods, rising obesity rates, sleep deprivation, environmental toxins, and chronic stress are especially prominent (Sungur, 2023; Özden, 2021). In particular, an inverse relationship between screen time and attention span has been noted; individuals accustomed to short bursts of attention tend to develop a greater need for constant stimulation (Wallace & Milev, 2017).

At the neurobiological level, attention deficit has been associated with volumetric reductions and functional impairments in brain regions responsible for executive functioning, such as the prefrontal cortex, anterior cingulate cortex, basal ganglia, and cerebellum (Hoogman et al., 2017). Functional magnetic resonance imaging (fMRI) studies have demonstrated reduced activity, connectivity issues, and structural volume loss in these areas. Notably, impairments in synaptic transmission of neurotransmitters such as dopamine and norepinephrine play a critical role in attention regulation (Arnsten & Rubia, 2012).

At the genetic level, polymorphisms in the dopamine transporter gene (DAT1), dopamine receptor genes (DRD4, DRD5), serotonin transporter gene (5-HTT), and catechol-O-methyltransferase (COMT)—involved in norepinephrine metabolism—are recognized as biomarkers that increase the risk for ADHD (Faraone et al., 2015; Sungur, 2023). In addition to these biological bases, preterm birth, low birth weight, prenatal exposure to tobacco and alcohol, and early life psychological trauma are also important risk factors linked to the development of attention deficit (Thapar & Cooper, 2016).

Recent evaluations through the lens of functional medicine and psychoneuroimmunology suggest that attention deficit is not solely a neurological issue but also involves multiple systems, including immune dysregulation, microbiota imbalance, inflammation, detoxification issues, and circadian rhythm disturbances (Sungur, 2023). Therefore, in addition to classical neurobiological explanations, holistic and systemic approaches are increasingly gaining importance in the assessment of attention deficit.

The gut-brain axis is a complex bidirectional communication system between the gastrointestinal tract and the central nervous system, mediated through neural, hormonal, immune, and microbial signaling pathways (Mayer et al., 2015). This communication network operates via the vagus nerve, cytokines, microbiota-derived metabolites, and the hypothalamic-pituitary-adrenal (HPA) axis (Cryan & Dinan, 2012). Recent studies have shown that this axis influences not only digestive functions but also mood regulation, stress management, cognitive performance, and attention-related neuropsychological processes (Dinan & Cryan, 2017).

2. WHAT IS THE MICROBIOTA?

The microbiota is defined as a dynamic microbial community composed of bacteria, viruses, fungi, and archaea that colonize various regions of the human body, including the skin, respiratory tract, and especially the intestines. The genetic material carried by these microbial communities—known as the microbiome—contains approximately 100 times more information than the human genome (Sender et al., 2016). The microbiota serves as a unique biological signature of each individual and is shaped by numerous factors such as mode of delivery (vaginal vs. cesarean), breastfeeding duration, dietary

patterns, antibiotic use, age, environmental exposures, and even maternal stress during pregnancy (Hooper, Littman & Macpherson, 2012; Belkaid & Hand, 2014; Tamburini et al., 2016; Matas-Blanco & Caparrós-González, 2020).

The gut microbiota performs a wide range of functions that extend beyond the digestive system. These include the fermentation of indigestible fibers into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate; the maintenance of intestinal mucosal integrity; the training of the immune system; the synthesis of vitamins K and B12; and the modulation of neurotransmitter production such as serotonin, dopamine, and GABA (Silva et al., 2020). This microbial composition, which is shaped during early life, has long-term effects on both immune development and neurodevelopmental processes. For example, infants born via cesarean section have been shown to exhibit lower microbial diversity and altered immune regulation compared to those born vaginally. Similarly, shorter durations of breastfeeding are associated with a reduction in beneficial gut bacteria (Belkaid & Hand, 2014; Matas-Blanco & Caparrós-González, 2020).

An imbalance in the microbiota—known as dysbiosis—can lead to increased intestinal permeability ("leaky gut"), activation of inflammatory responses, decreased neurotransmitter production, and consequently, impairments in attention, concentration, and mood regulation (Sungur, 2023; Kamada et al., 2013). These impairments are not limited to the gastrointestinal system but may also affect the central nervous system via the gut-brain axis.

2.1 Major Microbial Phyla and Their Functional Properties

The dominant bacterial phyla in the gut microbiota include:

- **Firmicutes:** Includes genera such as *Lactobacillus*, *Clostridium*, and *Ruminococcus*. This group plays a critical role in SCFA production, supporting epithelial integrity and host–microbiota mutualism. Notably, SCFA-producing species such as *Clostridium* and *Ruminococcus* regulate gut–epithelial interactions. However, a disproportionate increase in Firmicutes has been linked to various metabolic and neuropsychiatric disorders, including obesity, insulin resistance, and neuroinflammation-related behavioral changes (Valdes et al., 2018; Zmora et al., 2019).

- **Bacteroidetes:** Includes *Bacteroides* and *Prevotella* species, which are involved in fermenting dietary fibers into SCFAs. A higher abundance of Bacteroidetes is generally associated with better metabolic health (Rooks & Garrett, 2010; Silva et al., 2020; Belkaid & Hand, 2014).
- **Actinobacteria:** Primarily represented by *Bifidobacterium* species, which are notable for their ability to produce GABA (gamma-aminobutyric acid), regulate immune responses, and influence neurological functions via the brain–gut axis (Barrett et al., 2012).
- **Proteobacteria:** This phylum includes species such as *Escherichia coli*, *Salmonella*, and *Helicobacter*. An overabundance of Proteobacteria is associated with increased gut permeability and systemic inflammation (Hooper et al., 2012; Kamada et al., 2013).
- **Verrucomicrobia:** Best known for *Akkermansia muciniphila*, which supports mucosal barrier integrity and metabolic health (Everard et al., 2013).

2.2 The Relationship Between Attention Deficit and the Microbiota

Recent studies have revealed significant alterations in the gut microbiota of individuals diagnosed with attention deficit. Commonly observed microbial imbalances in these individuals include:

- An increased Firmicutes/Bacteroidetes ratio
- A marked decrease in *Prevotella* species
- An overrepresentation of Proteobacteria
- Reduced SCFA production (Aarts et al., 2017; Prehn-Kristensen et al., 2018)

Furthermore, different microbiota profiles have been reported depending on ADHD subtypes:

- **Inattentive type:** Decreased *Prevotella* and lower SCFA levels
- **Hyperactive-impulsive type:** Increased abundance of pro-inflammatory bacteria
- **Combined type:** Decreased microbial diversity and generalized dysbiosis (Sungur, 2023)

These findings suggest that attention deficit is not solely a neurotransmitter-based disorder, but may also involve microbial and immunological dysregulation. Within the framework of functional medicine, microbiota-supporting interventions such as probiotic supplementation, prebiotic-rich diets, and increased fiber intake may contribute to symptom management in these individuals (Wallace & Milev, 2017).

3. MICROBIOTA AND NEUROTRANSMITTER PRODUCTION

In the previous section, the general physiological functions of the gut microbiota and its relationship with Attention Deficit Hyperactivity Disorder (ADHD) were addressed. This section focuses more specifically on the impact of the microbiota on neurotransmitter production. Neurotransmitters are chemical messenger molecules that enable communication between neurons and play a central role in regulating attention, learning, memory, motivation, mood, and behavior (Dinan & Cryan, 2017).

Traditionally, it was believed that neurotransmitters were produced exclusively within the central nervous system. However, recent studies have shown that a significant portion can also be synthesized in the gastrointestinal tract, particularly by the gut microbiota (Strandwitz, 2018).

Microorganisms residing in the gut actively participate in the direct or indirect synthesis of various neurotransmitters. These molecules can influence neuropsychological processes by communicating with the brain either through the bloodstream or via the vagus nerve. The neurochemical modulation exerted by the gut microbiota is increasingly considered a critical factor in understanding the etiology of many neurodevelopmental and psychiatric disorders, including ADHD (Sudo et al., 2004; Wallace & Milev, 2017).

3.1. Major Neurotransmitters Produced by the Microbiota

- **Serotonin (5-HT):** Approximately 90% of the body's serotonin is synthesized in the gastrointestinal system. Species such as *Lactobacillus*, *Streptococcus*, and *Enterococcus* are involved in the metabolism of tryptophan, a precursor of serotonin (Yano et al., 2015). Serotonin plays key roles in mood regulation, sleep–wake cycles, and attentional control.

- **Dopamine:** Dopamine is involved in motivation, goal-directed behavior, and attentional processes. It can be synthesized by species such as *Bacillus* and *Escherichia coli* (Strandwitz, 2018). Dysregulation of dopamine levels has been associated with inattentiveness and deficits in reward processing, which are frequently observed in ADHD (Arnsten & Rubia, 2012).
- **GABA (Gamma-Aminobutyric Acid):** As the primary inhibitory neurotransmitter, GABA regulates anxiety and enhances mental clarity. *Lactobacillus* and *Bifidobacterium* species are known to contribute to GABA production (Barrett et al., 2012). Reduced GABA levels have been linked to symptoms of hyperactivity and impulsivity.
- **Acetylcholine:** Acetylcholine plays a vital role in memory, sustained attention, and learning capacity. Certain strains of *Lactobacillus plantarum* are capable of modulating its production. This neurotransmitter is particularly influential in cognitive domains such as working memory and verbal learning (Cryan & Dinan, 2018).

3.2 Dysbiosis and Neurochemical Imbalance

Imbalances in the gut microbiota—referred to as dysbiosis—can adversely affect the production of the aforementioned neurotransmitters. A reduction in short-chain fatty acid (SCFA) synthesis may suppress dopamine release, while increased intestinal permeability (leaky gut) allows lipopolysaccharides (LPS) to enter systemic circulation, triggering neuroinflammatory responses and disrupting synaptic plasticity (Kelly et al., 2015). These biochemical alterations suggest a functional link between gut microbiota and the neurobiological mechanisms underlying ADHD (Sungur, 2023).

From a functional medicine perspective, treatment approaches for such conditions should not focus solely on the central nervous system but also aim to restore gastrointestinal balance. Interventions such as probiotic and prebiotic supplementation, anti-inflammatory dietary patterns, and fiber-rich nutrition can help regulate the microbiota and support neurotransmitter synthesis (Dinan & Cryan, 2017; Wallace & Milev, 2017).

Although attention deficit and ADHD have long been framed within the context of neurochemical imbalances, recent translational research indicates that these disorders may also be linked to disturbances in the gut microbiota (Aarts et al., 2017; Sungur, 2023). Microbiome studies based on both human and animal models have revealed dysbiotic findings in individuals diagnosed with ADHD, such as reduced alpha diversity (microbial richness), disproportionate increases or decreases in certain bacterial species, and impaired gut permeability (Prehn-Kristensen et al., 2018).

3.3 Indicators of Microbial Imbalance

1. **Increased Firmicutes/Bacteroidetes Ratio:** In neuropsychiatric conditions like attention deficit disorder, a disrupted balance between these two dominant phyla—characterized by a relative increase in Firmicutes and decrease in Bacteroidetes—has been reported. This shift may influence both energy metabolism and inflammatory pathways (Rooks & Garrett, 2010).
2. **Reduced Prevotella Abundance:** Lower levels of *Prevotella* species, which play a role in SCFA production (particularly propionate and butyrate), are associated with mucosal barrier disruption, increased intestinal permeability, and neuroinflammation—commonly observed in individuals with attention deficits (Aarts et al., 2017).
3. **Increased Proteobacteria and Enterobacteriaceae:** These taxa include bacteria with high pathogenic potential, which may increase LPS production and activate the immune system. This, in turn, can lead to neuroinflammation and cognitive dysfunction (Belkaid & Hand, 2014; Kamada et al., 2013).
4. **Decreased SCFA Production (Especially Butyrate):** Lower levels of butyrate—critical for gut epithelial integrity, brain development, and neurotransmitter release—may contribute to cortical dysfunctions linked to ADHD (Silva et al., 2020).
5. **Clostridium Imbalance:** Certain *Clostridium* species are involved in dopamine metabolism. Overgrowth or dominance of specific *Clostridium* strains can lead to neurochemical imbalances (Strandwitz, 2018).

3.4 Neurobiological Reflections of Microbial Imbalance

- **Neuroinflammation:** Dysbiosis leads to increased pro-inflammatory signaling and activation of microglial cells. This process has been linked to structural and functional impairments, particularly in brain regions such as the prefrontal cortex, which play a role in attention regulation (Kelly et al., 2015).
- **Metabolic Endotoxemia:** Increased intestinal permeability allows bacterial endotoxins to enter systemic circulation. This condition, known as metabolic endotoxemia, can negatively affect synaptic plasticity and reduce cognitive performance (Sudo et al., 2004).
- **Neurotransmitter Dysregulation:** Disruptions in the microbial production of key neurotransmitters—such as serotonin, dopamine, and GABA—may further deepen the biochemical basis of attention deficit (Strandwitz, 2018; Sungur, 2023).

3.5 Microbial Profiles Across ADHD Subtypes

Recent microbiota-based research indicates that distinct microbial profiles may be associated with different ADHD subtypes:

- **Predominantly Inattentive Type:** This group typically shows low levels of SCFA-producing bacteria, reduced microbial diversity, and decreased *Prevotella* abundance. Such microbial patterns are correlated with cognitive slowing and difficulties in maintaining focus (Prehn-Kristensen et al., 2018).
- **Predominantly Hyperactive-Impulsive Type:** A predominance of pro-inflammatory bacterial species is observed, which is correlated with immune system overactivation and increased irritability (Aarts et al., 2017).
- **Combined Type:** Both reduced microbial diversity and markers of systemic inflammation are present, potentially contributing to a more persistent and widespread clinical presentation (Sungur, 2023).

These findings suggest that the etiology of ADHD is not limited to biochemical alterations within the central nervous system, but also involves

environmental, microbial, and immunological components. Therefore, personalized and microbiome-targeted strategies may offer a complementary role in the management of ADHD.

4. NUTRITIONAL MODULATION OF THE MICROBIOTA: AN EVALUATION IN THE CONTEXT OF ATTENTION DEFICIT

The gut microbiota is a highly dynamic structure that is sensitive to environmental influences. Among these, nutrition stands out as one of the most critical determinants of microbiota composition and metabolic activity (Cryan & Dinan, 2012). The macro- and micronutrients obtained from the diet can influence the diversity, distribution, and function of gut bacteria, thereby affecting neurocognitive processes via the gut-brain axis. In this context, microbiota-targeted nutritional strategies are gaining increasing attention in the management of neurodevelopmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD) (Sungur, 2023).

4.1 Diet Components That Support the Microbiota

Modulating the gut microbiota through diet plays a crucial role in supporting both gastrointestinal and neuropsychiatric health. The following dietary components have been highlighted in this regard:

- **Prebiotic Fibers:** These include soluble fibers such as inulin, fructooligosaccharides (FOS), and beta-glucans, which promote the growth of beneficial bacteria—particularly *Bifidobacterium* and *Lactobacillus*. Inadequate intake of these fibers may reduce the production of short-chain fatty acids (SCFAs), especially butyrate, which can weaken the gut barrier and trigger neuroinflammation, thereby exacerbating ADHD symptomatology (Licinio et al., 2024).
- **Probiotics:** Naturally present in fermented dairy products like kefir and yogurt, live microorganisms help maintain microbiota balance. Strains such as *Lactobacillus rhamnosus* and *Bifidobacterium longum* have been shown to modulate dopaminergic and GABAergic systems, potentially reducing behavioral symptoms associated with ADHD (Wallace & Milev, 2017).

- **Polyphenols:** These plant-based antioxidants (e.g., green tea, blueberries, olive oil) suppress inflammation and promote the proliferation of beneficial species like *Akkermansia muciniphila*. These bacteria help strengthen the mucosal barrier, playing a role in preventing leaky gut syndrome (Scalbert et al., 2014).
- **Omega-3 Fatty Acids:** Long-chain omega-3 fatty acids such as EPA and DHA can influence both the gut microbiota and the central nervous system, enhancing neuroplasticity. Randomized controlled trials have demonstrated that omega-3 supplementation can improve attention span and executive functions in children (Richardson & Montgomery, 2005).

4.2 Dietary Components That May Harm the Microbiota

Certain dietary components commonly found in modern diets can disrupt the balance of the gut microbiota, paving the way for dysbiosis. These elements may also interfere with gut-brain axis communication and contribute to declines in cognitive function:

- **Refined Carbohydrates and Sugars:** Excessive consumption of fructose and glucose has been shown to promote the proliferation of pro-inflammatory bacteria such as *Escherichia coli* and *Clostridium difficile*. This microbial shift can lead to inflammation, endotoxemia, and increased intestinal permeability (Silva et al., 2020).
- **Artificial Sweeteners:** High-intensity artificial sweeteners such as neotame have been shown in mouse models to reduce microbial diversity, decrease Firmicutes levels, and increase Bacteroidetes levels after four weeks of consumption. Additionally, the expression of genes associated with butyrate production was suppressed, which may negatively affect gut barrier integrity, energy metabolism, and overall host health (Chi et al., 2018).
- **Emulsifiers and Food Additives:** Emulsifiers such as carboxymethylcellulose and polysorbate may damage the intestinal mucosa and disrupt the symbiotic relationship between the host and microbiota. This disruption can trigger excessive immune activation (Chassaing et al., 2015).

4.3 Nutritional Approaches in Individuals with Attention Deficit

In individuals diagnosed with attention deficit, nutritional strategies aimed at supporting the microbiota are increasingly considered complementary approaches in clinical settings:

- **Mediterranean Diet:** This dietary model, rich in whole grains, vegetables, fruits, olive oil, fish, and fermented foods, enhances microbial diversity and reduces systemic inflammation through its high content of fiber, polyphenols, and omega-3 fatty acids. Studies have shown that higher adherence to the Mediterranean diet is associated with reduced symptoms of ADHD (Ríos-Hernández et al., 2017).
- **Elimination Diets:** In individuals suspected of having sensitivities to gluten, casein, artificial colorants, or food additives, removing specific dietary components may help alleviate symptoms. However, this approach requires professional supervision; if misapplied, it may lead to nutritional deficiencies and further microbial disruption (Pelsser et al., 2011).

5. MANAGEMENT OF ATTENTION DEFICIT THROUGH THE FUNCTIONAL MEDICINE APPROACH

Functional medicine is a personalized and systems biology-based health model that evaluates an individual's health not merely through the symptoms presented but by identifying and addressing the underlying root causes of those symptoms (Bland, 2019). In recent years, the potential clinical benefits of functional medicine approaches—particularly in the management of multifactorial neurodevelopmental disorders such as ADHD—have gained increasing attention. These approaches target various areas including nutrition, microbiota balance, inflammation regulation, sleep patterns, and toxic burden (Sungur, 2023; Dinan & Cryan, 2017).

From a functional medicine perspective, ADHD is not solely a neurological disorder limited to dysfunctions in the dopaminergic system. Rather, it is viewed as a systemic imbalance that emerges from the interaction of multiple factors, including genetic predispositions, epigenetic modifications, nutritional status, gut microbiota composition, inflammatory load,

detoxification capacity, sleep quality, and stress regulation (Sungur, 2023; Ríos-Hernández et al., 2017).

5.1 Holistic Assessment Parameters

Functional medicine practitioners evaluate ADHD through an integrated lens, considering the interplay of multiple physiological systems and clinical parameters:

- **Gut Microbiota:** Dysbiosis, reduced microbial diversity, and impaired SCFA production may influence neurotransmitter levels and neuroinflammation. Functional assessments often utilize stool-based analyses such as GI-MAP or 16S rRNA sequencing (Prehn-Kristensen et al., 2018; Kelly et al., 2015).
- **Nutrient Deficiencies:** Deficiencies in key micronutrients such as iron, zinc, magnesium, vitamin B12, and vitamin D can significantly impact central nervous system functioning. These nutrients play crucial roles in neurobiological processes including dopamine synthesis, mitochondrial energy production, and synaptic plasticity. Their inadequacy may impair neurotransmitter synthesis, disrupt energy metabolism, and weaken neuronal communication—potentially contributing to mood disorders and neuropsychiatric conditions such as attention deficits (Rao et al., 2008; Carocci et al., 2021).
- **Chronic Inflammation:** Elevated levels of CRP, TNF-α, and IL-6 indicate systemic inflammation and its potential contribution to neuroinflammatory states. This can directly affect the prefrontal cortex and executive functions (Khandaker et al., 2014).
- **Detoxification Capacity:** The activity of hepatic phase I and II enzymes, glutathione reserves, and the individual burden of heavy metals (e.g., lead, mercury) should be evaluated. Recent studies suggest that environmental toxin load can contribute to attentional and behavioral problems via mechanisms involving inflammation and neurotransmitter metabolism (Zhang et al., 2024).
- **Sleep and Circadian Rhythm:** Melatonin levels, nighttime light exposure, sleep quality, and sleep onset latency are closely linked to ADHD symptomatology. Research indicates that sleep onset difficulties

in children with ADHD are associated with circadian misalignment and behavioral issues (Gruber et al., 2012).

- **Stress and the HPA Axis:** Psychological stress during pregnancy may activate the hypothalamic-pituitary-adrenal (HPA) axis, resulting in elevated cortisol levels. This can disrupt neurodevelopmental processes by impairing prefrontal cortex and hippocampal development, affecting attention, executive functioning, and emotional regulation. Monitoring cortisol secretion may provide a biological marker for such dysfunctions (Matas-Blanco & Caparros-Gonzalez, 2020).

5.2 Intervention Strategies

In functional medicine, the management of ADHD does not exclude pharmacological treatment but rather supports it through individualized strategies tailored to the person's biological and environmental context.

These strategies include:

- **Restructuring the Gut Microbiota:** A diet rich in fiber, fermented foods, and targeted probiotic and prebiotic supplementation may help restore microbial balance. When necessary, elimination diets can be implemented to control inflammatory responses and support the gut-brain axis (Dinan & Cryan, 2017; Licinio et al., 2024).
- **Targeted Micronutrient Supplementation:** Based on individual deficiencies, supplements such as magnesium bisglycinate, methylcobalamin (vitamin B12), active B-complex vitamins, iron bisglycinate, vitamin D3, and omega-3 fatty acids may be recommended (Ríos-Hernández et al., 2017).
- **Stress Regulation and Neuroendocrine Balance:** Stress management strategies may include breathing exercises, adaptogenic herbal supplements (e.g., ashwagandha), regular physical activity, and psychoeducation. Clinical data suggest that ashwagandha may reduce HPA axis activity by lowering cortisol and DHEA-S levels (Lopresti et al., 2019).
- **Sleep Hygiene and Circadian Alignment:** To promote sleep hygiene and circadian synchronization, it is recommended to reduce blue light exposure, limit screen use before bedtime, sleep in a dark and quiet

environment, establish consistent sleep routines, and use supplements such as melatonin if necessary (Gruber et al., 2012).

- **Lifestyle Support for Neuroplasticity:** Outdoor activities, mindfulness practices, nature exposure, exercise, and mind-body integrative programs (e.g., yoga) can strengthen synaptic functions and enhance neuroplasticity (Davidson & McEwen, 2012).

CONCLUSION AND RECOMMENDATIONS

Attention Deficit Hyperactivity Disorder (ADHD) is now recognized not merely as a neurochemical disorder of the central nervous system but as a multifactorial neurodevelopmental condition closely linked to the gut microbiota, immune system, nutritional status, stress response, circadian rhythm, and detoxification processes (Sungur, 2023; Dinan & Cryan, 2017). This review has evaluated the role of the gut-brain-microbiota axis in ADHD pathophysiology, emphasizing microbial diversity, short-chain fatty acid (SCFA) production, neurotransmitter synthesis, and neuroinflammation.

While conventional treatment models may effectively suppress symptoms, they often fall short of addressing the underlying physiological imbalances. Research has shown that dysbiosis, micronutrient deficiencies, toxic exposure, sleep disturbances, and HPA (hypothalamic-pituitary-adrenal) axis dysfunction can directly impact the manifestation of ADHD symptoms (Zhang et al., 2024).

Within this framework, the functional medicine approach offers several recommendations for ADHD management:

- **Modulation of the Gut Microbiota:** Personalized probiotic and prebiotic interventions guided by microbiome analyses should be implemented. Strains such as *Lactobacillus rhamnosus* and *Bifidobacterium longum* have demonstrated regulatory effects on dopaminergic and GABAergic systems (Dinan & Cryan, 2017).
- **Dietary Patterns:** A Mediterranean-style diet rich in fiber, omega-3 fatty acids, polyphenols, and fermented foods should be encouraged, while processed foods and additives should be limited as much as possible (Ríos-Hernández et al., 2017; Scalbert et al., 2004).

- **Monitoring and Supplementation:** Micronutrients such as zinc, magnesium, vitamin B12, vitamin D, and omega-3 fatty acids play essential roles in neurocognitive function, immune regulation, and neurotransmitter metabolism. Their serum levels should be monitored regularly, and deficiencies should be corrected with bioavailable forms tailored to individual needs. This strategy may optimize therapeutic outcomes and reduce relapse risk in the long term (Carocci et al., 2021).
- **Sleep Optimization:** Blue light exposure should be minimized, circadian-friendly lifestyle habits that support melatonin production should be promoted, and, if necessary, professional guidance for sleep support supplements should be provided (Licinio et al., 2024).
- **Stress Management:** Stress regulation should include breathing exercises, adaptogenic herbs (e.g., ashwagandha, rhodiola), mindfulness practices, and nature-based interventions. Monitoring cortisol rhythms can also offer insights into biological stress responses (Davidson & McEwen, 2012).
- **Toxic Load Evaluation:** Exposure to heavy metals and pesticides should be assessed. Detoxification systems—especially glutathione pathways—should be supported through targeted nutrition to mitigate the neurological effects of environmental toxins (Zhang et al., 2024).
- **Psychosocial Interventions:** Cognitive Behavioral Therapy (CBT), psychoeducation, and family counseling should accompany biological interventions to ensure a holistic treatment approach (Pelsser et al., 2011).

Emerging data suggest that probiotics, prebiotics, low-glycemic anti-inflammatory diets, and micronutrient supplementation may significantly reduce ADHD symptoms. Notably, personalized microbiome-based treatment protocols have shown promising improvements in attention span and behavioral regulation (Licinio et al., 2024).

In conclusion, ADHD should not be seen solely as a brain-centered disorder but as the outcome of multiple systemic physiological imbalances. Functional medicine offers a multidimensional, root-cause-oriented, and personalized framework that is expected to gain broader acceptance in the future management of ADHD.

Additionally, as the author of this study, I bring a unique perspective—not only as a nutritionist but also as a primary school teacher. ADHD is not solely observable through laboratory parameters; it manifests clearly within the classroom—through children's attention spans, engagement with learning, peer interactions, and communication with their teachers.

My experiences as an educator have shown that children with ADHD often face the risk of being labeled and misunderstood due to a lack of awareness regarding individual differences. Therefore, it is crucial that teachers be equipped not only with pedagogical knowledge but also with fundamental insights into neurobiology, microbiota, and nutritional psychology. Early awareness, timely referrals, and effective collaboration across disciplines are vital.

In-classroom strategies—such as micro-breaks adjusted to attention spans, structured seating arrangements, and visual stimulus control—combined with nutritional awareness and conscious communication with families, can foster not only academic success but also the child's overall development. One of the aims of this work is to build bridges between the fields of education and health, promoting multidisciplinary, child-centered approaches to ADHD.

REFERENCES

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). American Psychiatric Publishing.

Aarts, E., Ederveen, T. H., Naaijen, J., Zwiers, M. P., van Rooij, D., Schweren, L. J., ... & Buitelaar, J. K. (2017). Gut microbiome in ADHD and its relation to neural reward anticipation. *PLOS ONE, 12*(9), e0183509.

Arnsten, A. F. T., & Rubia, K. (2012). Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: Disruptions in neurodevelopmental psychiatric disorders. *Journal of the American Academy of Child & Adolescent Psychiatry, 51*(4), 356–367.

Barrett, E., Ross, R. P., O'Toole, P. W., Fitzgerald, G. F., & Stanton, C. (2012). γ-Aminobutyric acid production by culturable bacteria from the human intestine. *Journal of Applied Microbiology, 113*(2), 411–417.

Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. *Cell Host & Microbe, 16*(2), 135–145. https://www.cell.com/cell-host-microbe/pdf/S1931-3128(14)00426-0.pdf

Bland, J. S. (2019). Systems biology meets functional medicine: Creating synthesis. *Integrative Medicine: A Clinician's Journal*, 18(5), 14–18.

Carocci, A., Catalano, A., Lauria, G., Sinicropi, M. S., & Genchi, G. (2021). Micronutrients in mental health: A review of current findings. *Nutrients, 13*(2), 411.

Cenit, M. C., Sanz, Y., & Codoñer-Franch, P. (2017). Influence of gut microbiota on neuropsychiatric disorders. World Journal of Gastroenterology, 23(30), 5486–5498. https://doi.org/10.3748/wjg.v23.i30.5486

Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C., Srinivasan, S., Ley, R. E., & Gewirtz, A. T. (2015). Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. *Nature, 519*(7541), 92–96.

Chi, L., Bian, X., Gao, B., Tu, P., Lai, Y., Ru, H., & Lu, K. (2018). Effects of the artificial sweetener neotame on the gut microbiome and fecal metabolites in mice. *Molecules*, 23(2), 367. https://doi.org/10.3390/molecules23020367

Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience, 13*(10), 701–712.

Dalmiş, U., & Yıldırım, İ. G. (2025). Otizm spektrum bozukluğunda beslenme tedavisi yaklaşımları. *Journal of Autism and Health Sciences Online, 1*(1), 1–15.

Davidson, R. J., & McEwen, B. S. (2012). Social influences on neuroplasticity: Stress and interventions to promote well-being. *Nature Neuroscience, 15*(5), 689–695.

Dinan, T. G., & Cryan, J. F. (2017). The microbiome–gut–brain axis in health and disease. *Gastroenterology Clinics of North America, 46*(1), 77–89.

Dziegielewski, S. F. (2014). *DSM-5 in action* (3rd ed.). John Wiley & Sons

Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., ... & Cani, P. D. (2013). Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proceedings of the National Academy of Sciences, 110*(22), 9066–9071.

Faraone, S. V., Larsson, H., & Asherson, P. (2015). The genetics of attention deficit hyperactivity disorder. *Biological Psychiatry, 57*(11), 1313–1323.

Gruber, R., Fontil, L., Bergmame, L., Wiebe, S. T., Amsel, R., Frenette, S., & Carrier, J. (2012). Contributions of circadian tendencies and behavioral problems to sleep onset problems of children with ADHD. *BMC Psychiatry, 12*, 212. https://doi.org/10.1186/1471-244X-12-212

Güven, E. (2023). *Dikkat eksikliği bozukluğunun yetişkinlik dönemine etkileri*

Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012). Interactions between the microbiota and the immune system. *Immunity, 39*(3), 213–232. https://www.cell.com/immunity/pdf/S1074-7613(12)00421-9.pdf

Kamada, N., Chen, G. Y., Inohara, N., & Núñez, G. (2013). Control of pathogens and pathobionts by the gut microbiota. *Cell Host & Microbe, 14*(6), 765–776. https://www.cell.com/cell-host-microbe/pdf/S1931-3128(14)00063-8.pdf

Kelly, J. R., Borre, Y., O'Brien, C., Patterson, E., El Aidy, S., Deane, J., ... & Dinan, T. G. (2015). Transferring the blues: Depression-associated gut

microbiota induces neurobehavioural changes in the rat. *Journal of Psychiatric Research*, 82, 109–118.

Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014). Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life. *JAMA Psychiatry, 71*(10), 1121–1128.

Licinio, J., Bornstein, S. R., Pavlatou, M. G., Baranchuk, N., Wong, M. L., & De la Fuente-Fernández, R. (2024). Gut microbiota and attention deficit hyperactivity disorder: New perspectives for a challenging condition. *Frontiers in Psychiatry*, 15, 1279266. https://doi.org/10.3389/fpsyt.2024.1279266

Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). *An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study.* Medicine, 98(37), e17186. https://doi.org/10.1097/MD.0000000000017186

Matas-Blanco, C., & Caparros-Gonzalez, R. A. (2020). Influence of maternal stress during pregnancy on child's neurodevelopment: A systematic review. *Psych*, 2(4), 186–197. https://doi.org/10.3390/psych2040016

Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. *The Journal of Clinical Investigation, 125*(3), 926–938.

Özden, Ö. F. (2021). *Dikkat eksikliği ve tedavi yöntemleri* (Yüksek lisans tezi, İstanbul Gelişim Üniversitesi, Sosyal Bilimler Enstitüsü). Yükseköğretim Kurulu Ulusal Tez Merkezi. https://tez.yok.gov.tr

Pelsser, L. M., Frankena, K., Toorman, J., & Rodrigues Pereira, R. (2011). Diet and ADHD, reviewing the evidence: A systematic review of meta-analyses of double-blind placebo-controlled trials evaluating the efficacy of diet interventions on the behavior of children with ADHD. *PLOS ONE, 6*(1), e16028.

Prehn-Kristensen, A., Zimmermann, A., Tittmann, L., Lieb, W., Schreiber, S., Baving, L., & Fischer, A. (2018). Reduced microbiome alpha diversity in young patients with ADHD. *PLOS ONE, 13*(7), e0200728.

Polanczyk, G., Salum, G. A., Sugaya, L. S., Caye, A., & Rohde, L. A. (2015). Annual research review: A meta-analysis of the worldwide prevalence of

mental disorders in children and adolescents. *Journal of Child Psychology and Psychiatry, 56*(3), 345–365.

Rao, T. S. S., Asha, M. R., Ramesh, B. N., & Jagannatha Rao, K. S. (2008). Understanding nutrition, depression and mental illnesses. *Indian Journal of Psychiatry, 50*(2), 77–82.

Richardson, A. J., & Montgomery, P. (2005). The Oxford-Durham study: A randomized, controlled trial of dietary supplementation with omega-3 and omega-6 fatty acids in children with developmental coordination disorder. *Pediatrics*, 115(5), 1360–1366. https://doi.org/10.1542/peds.2004-2164

Ríos-Hernández, A., Alda, J. A., Farran-Codina, A., Ferreira-García, E., & Izquierdo-Pulido, M. (2017). The Mediterranean diet and ADHD in children and adolescents. *Pediatrics, 139*(2), e20162027.

Rooks, M. G., & Garrett, W. S. (2010). Gut microbiota, metabolites and host immunity. *Cell Host & Microbe, 8*(4), 292–300. https://www.cell.com/cell-host-microbe/pdf/S1931-3128(10)00276-3.pdf

Scalbert, A., Johnson, I. T., & Saltmarsh, M. (2004). Polyphenols: Antioxidants and beyond. *The American Journal of Clinical Nutrition, 81*(1), 215S–217S.

Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. *PLOS Biology, 14*(8), e1002533.

Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020). The role of short-chain fatty acids from gut microbiota in gut-brain communication. *Frontiers in Endocrinology, 11*, 25.

Sungur, E. N. (2023). *Dikkat eksikliği bozukluğunda mikrobiyota ve nöroinflamasyon ilişkisi* (Uzmanlık tezi, İzmir Katip Çelebi Üniversitesi). Yükseköğretim Kurulu Ulusal Tez Merkezi. https://tez.yok.gov.tr

Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., ... & Koga, Y. (2004). Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. *The Journal of Physiology, 558*(1), 263–275.

Strandwitz, P. (2018). Neurotransmitter modulation by the gut microbiota. *Brain Research, 1693*, 128–133.

Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018). Role of the gut microbiota in nutrition and health. *BMJ*, 361, k2179. https://doi.org/10.1136/bmj.k2179

Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., ... & Hsiao, E. Y. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell, 161*(2), 264–276.

Zhang et al. (2024) *"Genetic associations and potential mediators between psychiatric disorders and irritable bowel syndrome: a Mendelian randomization study with mediation analysis"*.

Zmora, N., Suez, J., & Elinav, E. (2019). You are what you eat: Diet, health and the gut microbiota. *Nature Reviews Gastroenterology & Hepatology*, 16, 35–56.

Wallace, C. J. K., & Milev, R. (2017). The effects of probiotics on depressive symptoms in humans: A systematic review. *Annals of General Psychiatry, 16*(1), 14.

LIBERTY ACADEMIC is a part of LIBERTY PUBLISHER OF BOOKS
Head office New York, USA
+1 (314) 597-0372
80 Maiden Lane, 21st Floor /8 Water Street Corridor
New York, NY 10038